Adenosine deaminase, base editor and application

CN119053702APending Publication Date: 2024-11-29YOLTECH THERAPEUTICS CO LTD
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202380032939.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-04-07
Filing Date
2023-02-24
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

The existing CRISPR/Cas9 gene editing technology is inefficient in achieving single-base mutations, and the base editor has site dependence and a wide editing window, resulting in unnecessary editing and needs to be optimized to improve accuracy and efficiency.

Method used

By conducting site-directed mutagenesis of adenosine deaminase and combining it with a nucleic acid programmable nucleotide binding domain, the structure and function of the base editor are optimized, the editing efficiency of the adenine base editor is improved, and it is applied in eukaryotic cells .

Benefits of technology

It significantly improves the editing efficiency of the base editor, narrows the editing window, and enhances the accuracy of specific targets. It has potential clinical application prospects, especially in the treatment of hypercholesterolemia, beta-hemoglobinopathies and other diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119053702A_ABST
    Figure CN119053702A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biology, provides a deaminase and an adenine base editor, and further provides a mutated deaminase and a corresponding adenine base editor, the mutated deaminase is subjected to mutation of multiple amino acids compared with parent deaminase, so that the base editing efficiency is improved, and the application prospect is relatively good.
Need to check novelty before this filing date? Find Prior Art

Description

Adenosine deaminase, base editor and application thereof Technical Field

[0001] The present invention belongs to the field of biotechnology. More specifically, the present invention relates to an adenosine deaminase, a base editor fusion protein, a base editor system and uses. Background Art

[0002] How to modify the genome accurately and efficiently is an important goal of research in the field of life sciences, and CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) / Cas9-mediated gene editing technology has become the most powerful tool to achieve this goal. Traditional CRISPR / Cas9 technology generates double-strand breaks (DSBs) of DNA at the target site, thereby inducing homologous recombination (HR) and non-homologous end joining (NHEJ) repair pathways in the cell, thereby achieving site-specific knockout, replacement, insertion and other modifications of genomic DNA. However, it is difficult for DNA repair induced by DSB to achieve efficient and stable single-base mutations. Single nucleotide mutations can cause approximately 2 / 3 of human genetic diseases and are also the genetic basis for the variation of important traits in many animals and plants. Therefore, it is particularly important to develop a technology that can accurately and efficiently achieve single-base replacements. The base editor developed by David R. Liu's laboratory was born for this purpose. David R. Liu's laboratory has developed three different base editors, namely Cytosine Base Editor (CBE), Adenine Base Editor (ABE) and Prime Editor. These base editors do not rely on the generation of DSBs when working, nor do they require the participation of donor DNA.

[0003] Adenine base editing technology based on adenosine deaminase mainly utilizes a fusion protein composed of the nickase Cas9n (D10A) or dCas9 combined with adenosine deaminase. Under the guidance of sgRNA, the target base adenine A located in the base editing active window is deaminated to form hypoxanthine I, which is then gradually replaced by G after DNA repair25 and replication, ultimately forming a directed replacement from A to G (A to G).

[0004] Base editors can also treat some diseases by editing gene targets, such as hypercholesterolemia, transthyretin amyloidosis, and β-hemoglobinopathy. Therefore, optimizing existing base editors also has better prospects for clinical application.

[0005] However, current base editors have site-dependent differences in editing efficiency, and a wide editing window leads to unnecessary editing. Therefore, the modification of existing base editors is very necessary.

[0006] Summary of the Invention

[0007] The present invention discloses a deaminase, a base editor containing the same, and uses thereof. Through experiments and exploration, site-directed mutagenesis is performed on the basic sequence of the deaminase to obtain an adenine base editor with improved editing efficiency, thereby improving its editing efficiency in eukaryotic cells. A large number of experiments are also conducted on the structure of the base editor fusion protein, and a position suitable for the integration of adenosine deaminase into the nuclease domain is found, thereby obtaining a base editor fusion protein structure with improved editing efficiency, thereby obtaining better application prospects.

[0008] definition

[0009] It is well known to those skilled in the art that a protein can undergo amino acid changes, such as substitutions, deletions, or additions, and the resulting protein can maintain its function or activity.

[0010] The "substitution" mentioned above refers to the replacement of an amino acid residue at a certain position in an amino acid sequence by another amino acid residue; wherein, the "substitution" may be a conservative amino acid substitution.

[0011] "Conservative modification," "conservative substitution," or "conservative replacement" refers to replacing an amino acid in a protein with another amino acid having similar characteristics (e.g., charge, side chain size, hydrophobicity / hydrophilicity, main-chain conformation, and rigidity, etc.), such that changes can be made frequently without altering the biological activity of the protein.

[0012] Those skilled in the art will recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see Watson et al. (1987), Molecular Biology of the Gene, The Benjamin / Cummings Pub. Co., p. 224, (4th ed.)). In addition, substitutions with structurally or functionally similar amino acids are unlikely to disrupt biological activity. Exemplary conservative substitutions are set forth in "Exemplary Conservative Amino Acid Substitutions."

[0013] Exemplary conservative amino acid substitutions

[0014] As another example, amino acids with similar characteristics are shown below:

[0015] Unless otherwise defined, all technical and scientific terms used herein have the meaning commonly understood by those skilled in the art to which the invention belongs. As used herein, the following terms have the meanings ascribed to them below, unless otherwise indicated.

[0016] "Polynucleotide" and "nucleic acid" refer to a polymeric form of nucleotides (e.g., RNA or DNA) of any length. The term includes, but is not limited to, single-stranded, double-stranded, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derived nucleotide bases.

[0017] A "DNA sequence encoding a specific RNA" refers to a DNA nucleotide sequence that is transcribed into RNA.

[0018] "Regulatory element," "regulatory element," or "DNA regulatory sequence," "control element" refers to transcriptional and translational regulatory sequences such as promoters, enhancers, terminators, and the like.

[0019] A "promoter (also known as a promoter sequence)" is a DNA regulatory region that can bind RNA polymerase and initiate transcription of downstream (3' direction) coding or non-coding sequences. Generally speaking, various promoters, including inducible promoters, can be used to drive expression of various vectors of the present invention.

[0020] "Codon optimization" refers to the modification of a nucleic acid sequence to enable better expression of the aforementioned nucleic acid sequence in a host cell. Generally speaking, this is achieved by replacing at least one codon (for example, one or more, such as 10, 20 or more) in the original nucleic acid sequence with a codon that is more frequently or most frequently used in the host cell gene, while maintaining the expressed amino acid sequence.

[0021] "Naturally occurring" (also referred to as unmodified, unmodified, wild-type (wt)) refers to a nucleic acid, polypeptide, cell, or organism that occurs in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism that can be isolated from a source in nature is naturally occurring.

[0022] As used in this disclosure, the terms "polypeptide," "peptide," and "protein" are used interchangeably herein and refer to amino acid polymers of any length. The polymer may be linear or branched, it may contain modified amino acids, and it may be interrupted by non-amino acids. The term also includes amino acid polymers that have been modified (e.g., by disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation, or any other manipulation, such as conjugation with a labeling component). A "fusion protein" refers to a hybrid polypeptide that contains protein domains from at least two different proteins. One protein can be located at the amino-terminal (N-terminal) portion or the carboxyl-terminal (C-terminal) portion of the fusion protein, thereby forming an amino-terminal fusion protein or a carboxyl-terminal fusion protein, respectively.

[0023] A "CRISPR-Cas system" (also referred to as a "CRISPR system" or "CRISPR / Cas system") generally comprises transcripts or other elements associated with the expression of CRISPR-associated ("Cas") genes, or transcripts or other elements capable of directing the activity of the Cas genes. In some embodiments, components of a CRISPR system may comprise nucleic acids (e.g., vectors) encoding one or more components of the system, components in protein form, or a combination thereof.

[0024] "Cas protein" refers to a CRISPR-associated protein (Cas) (also referred to as a "CRISPR-associated protein," "CRISPR effector," "effector," "Cas protein," "Cas enzyme," or "CRISPR enzyme") that performs enzymatic activity and / or binds to a target site on a nucleic acid specified by an RNA guide. In some embodiments, a Cas protein has endonuclease, nickase, exonuclease, transposase, and / or excision activity; in other embodiments, the Cas protein may be nuclease-inactivated or partially inactivated.

[0025] "Guide RNA (also known as guide RNA, gRNA or crRNA)" refers to any RNA molecule that facilitates targeting of the Cas protein to a target nucleic acid (such as DNA and / or RNA). "Guide RNA" includes one or more guide RNAs and their equivalents known to those skilled in the art, including but not limited to RNA-based molecules capable of forming a complex with the Cas protein (e.g., direct repeat (DR) sequences), and comprising a sequence (e.g., a spacer) that has sufficient complementarity to the target nucleic acid sequence to hybridize with the target nucleic acid sequence and guide sequence-specific binding of the complex to the target nucleic acid sequence.

[0026] As used in this disclosure, the term "crRNA" includes a repeat sequence and a spacer sequence. CRISPR transcribes to form a long chain of pre-CRISPR RNA (pre-crRNA), and pre-crRNA is processed to obtain a short crRNA containing a repeat region sequence and a spacer region sequence. In some CRISPR / Cas systems, crRNA is obtained by the action of Cas protein on pre-crRNA. In other CRISPR / Cas systems, crRNA is obtained by the joint action of Cas protein and tracrRNA (trans-activating crRNA) on pre-crRNA.

[0027] In different CRISPR / Cas systems, crRNA can serve alone as a guide RNA (gRNA) to guide the Cas protein to the target sequence near the PAM sequence, or crRNA and tracrRNA can be combined into a single guide RNA (sgRNA) to guide the Cas protein to the target sequence near the PAM sequence.

[0028] As used in the present disclosure, "guide sequence of crRNA" refers to a sequence in crRNA that hybridizes with the target sequence of the target nucleic acid, which is correspondingly formed by the spacer sequence of crRNA.

[0029] As used in this disclosure, the term "target sequence" refers to a nucleotide sequence in a target nucleic acid that is complementary or at least partially complementary to crRNA. After the Cas protein, crRNA, and target sequence form a ternary complex, the Cas protein exerts specific cleavage activity on the target nucleic acid chain and / or non-nucleotide chain in the target nucleic acid. In this disclosure, "target sequence" and "target nucleic acid," "target polynucleotide," "target sequence," and "target nucleic acid sequence" can be used interchangeably.

[0030] As used in this disclosure, the term "target strand" refers to a nucleotide strand in a target nucleic acid that hybridizes with crRNA; the term "non-target strand" refers to a nucleotide strand in a target nucleic acid that does not hybridize with crRNA. The term "Cas9" or "Cas9 domain" refers to an RNA-guided nuclease comprising a Cas9 protein or a fragment thereof (e.g., a protein comprising an active, inactive, or partially active DNA cleavage domain of Cas9, and / or a binding domain of gRNA Cas9). Cas9 nuclease is sometimes also referred to as CRISPR-associated nuclease 9. As previously mentioned, CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements, and conjugative plasmids). The CRISPR cluster contains numerous short, conserved repeat regions and spacers. The CRISPR cluster is transcribed and processed into pre-crRNA. In the type II CRISPR / cas9 system, transcoded small RNA (tracrRNA), endogenous ribonuclease 3 (RNase III), and Cas9 protein are required for the correct processing of pre-crRNA. TracrRNA acts as a guide for ribonuclease 3 to assist in the processing of pre-crRNA. Subsequently, Cas9 / crRNA / tracrRNA endonucleolytic cleavage of linear or circular dsDNA targets complementary to the spacer sequence. Target chains that are not complementary to crRNA are cut by endonucleolytic cleavage. In nature, DNA binding and cleavage generally require proteins and two types of RNA. However, single guide RNA (sgRNA) can be engineered to integrate various aspects of crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M. et al., Science 337:816-821 (2012), the entire contents of which are incorporated herein by reference. Cas9 recognizes a short motif in the CRISPR repeat sequence (PAM or protospacer adjacent motif) to help distinguish self from non-self.Cas9 nuclease sequence and structure are well known to those skilled in the art (see, e.g., "Complete genome sequence of an M1 strain of Streptococcus pyogenes." Ferretti et al., Proc. Natl. Acad. Sci. USA 98:4658-4663 (2001); "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III." Deltcheva E. et al., Nature 471:602-607 (2011); and "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity." Jinek M. et al., Science 337:816-821 (2012)). Cas9 orthologs have been described in various species, including but not limited to Streptococcus pyogenes and Streptococcus thermophilus. Other suitable Cas9 nucleases and sequences will be apparent to those skilled in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from organisms and loci disclosed in Chylinski, Rhun, and Charpentier, “The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems” (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference.

[0031] Nuclease-inactivated Cas9 proteins are interchangeably referred to as "dCas9" proteins (nuclease-"dead" Cas9 or Cas9 without nuclease activity) or catalytically inactivated Cas9. It is known to generate Cas9 proteins (or fragments thereof) with inactive DNA cleavage domains (see, e.g., Jinek et al., Science. 337: 816-821 (2012); Qi et al. "Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression" (2013) Cell. 28; 152 (5): 1173-83). For example, it is known that the DNA cleavage domain of Cas9 includes two subdomains, the HNH nuclease subdomain and the RuvC subdomain. The HNH subdomain cuts the chain complementary to the gRNA, while the RuvC subdomain cuts the non-complementary chain. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, mutations D10A and H840A completely inactivate the nuclease activity of Streptococcus pyogenes Cas9 (Jinek et al., Science. 337: 816-821 (2012); Qi et al., Cell. 28: 152 (5): 1173-83 (2013)). Based on the knowledge in the art, additional suitable nuclease-inactive Cas9 domains will be apparent to those skilled in the art. Such additional exemplary suitable nuclease-inactive Cas9 domains include, but are not limited to, D10A / H840A, D10A / D839A / H840A, and D10A / D839A / H840A / N863A mutant domains (see, for example, Prashant et al., Nature Biotechnology. 2013; 31 (9): 833-838).

[0032] Cas9 nickase can cut a chain of double-stranded DNA. Cas9 nickase can be generated by introducing an inactivating mutation into the HNH subdomain or the RuvC subdomain. For example, an inactivating mutation (D10A) can be introduced into the RuvC domain of Streptococcus pyogenes Cas9, while the HNH domain remains active, i.e., the residue at position 840 remains as histidine. Such Cas9 variants can generate single-stranded DNA breaks (nicks) at specific positions based on the target sequence determined by gRNA. Those skilled in the art can identify the catalytic residues in the RuvC and HNH domains of any known Cas9 protein and introduce inactivating mutations to generate corresponding dCas9 or nCas9.

[0033] Similarly, for other Cas proteins, those skilled in the art can obtain the corresponding Cas proteins without nuclease activity and the nicking enzyme that cuts one strand of double-stranded DNA in the same manner.

[0034] As used in this disclosure, the term "deaminase" or "deaminase domain" refers to a protein or enzyme that catalyzes a deamination reaction. In some embodiments, the deaminase is an adenosine deaminase that catalyzes the hydrolytic deamination of adenine to hypoxanthine. In some embodiments, the deaminase is an adenosine deaminase that catalyzes the hydrolytic deamination of adenosine or adenine (A) to inosine (I). In some embodiments, the deaminase or deaminase domain is an adenosine deaminase that catalyzes the hydrolytic deamination of adenosine or deoxyadenosine to inosine or deoxyinosine, respectively. In some embodiments, adenosine deaminase catalyzes the hydrolytic deamination of adenosine in deoxyribonucleic acid (DNA).

[0035] As used in the present disclosure, the terms "nucleic acid programmable nucleotide binding domain", "nucleic acid programmable DNA-binding protein (napDNAbp)" refer to a protein that binds to a nucleic acid (e.g., DNA or RNA), such as a guide polynucleotide (e.g., gRNA), which guides the napDNAbp to a specific nucleic acid sequence, for example, by hybridizing with a target nucleic acid sequence. For example, the Cas9 protein can be bound to a guide RNA that guides the Cas9 protein to a specific DNA sequence that is complementary to the guide RNA. In some embodiments, the napDNAbp is a Cas9 domain, e.g., a nuclease-active Cas9, a Cas9 nickase (nCas9) or a nuclease-free Cas9 (dCas9). Examples of nucleic acid programmable DNA binding proteins include, but are not limited to, Cas9 (e.g., dCas9 and nCas9), CasX, CasY, Cpf1, C2c1, C2c2, C2c3, and Argonaute protein (AGO). However, it should be understood that nucleic acid programmable DNA binding proteins also include nucleic acid programmable proteins that bind RNA. For example, the napDNAbp can be bound to a nucleic acid that guides the napDNAbp to the RNA.Other nucleic acid programmable DNA binding proteins are also within the scope of the present disclosure, although they may not be specifically described in this disclosure.

[0036] The nCas9 domain comprises nCas9 or a fragment thereof, and the nCas9 fragment has a certain homology with nCas9 (e.g., at least about 70% homology, or at least about 80% homology, at least about 90% homology, at least about 95% homology, at least about 96% homology, at least about 97% homology, at least about 98% homology, at least about 99% homology, at least about 99.5% homology, or at least about 99.9% homology) and retains its basic function.

[0037] As used in the present disclosure, "base editor (BE)" or "nucleobase editor" refers to a reagent that binds to a polynucleotide and has nucleobase modification activity. In various embodiments, the base editor comprises a nucleobase modification polypeptide (e.g., a deaminase) and a nucleic acid programmable nucleotide binding domain (e.g., a nucleic acid programmable DNA binding protein) bound to a guide polynucleotide (e.g., a guide RNA). In various embodiments, the reagent is a biomolecule complex comprising a protein domain with base editing activity, i.e., capable of modifying bases (e.g., A, T, C, G, or U) in a nucleic acid molecule (e.g., DNA, RNA). In some embodiments, the polynucleotide programmable DNA binding domain is fused or connected to a deaminase domain. In one embodiment, the reagent is a fusion protein comprising a domain with base editing activity. In some embodiments, the domain with base editing activity can deaminize bases in nucleic acid molecules. In some embodiments, the base editor can deaminize one or more bases in a DNA molecule. In some embodiments, the base editor is an adenine base editor (ABE).

[0038] As used herein, "base editing activity" refers to the activity of chemically altering a base within a polynucleotide. In one embodiment, a first base is converted to a second base. In one embodiment, the base editing activity is adenosine or adenine deaminase activity, for example, converting a target A·T to C·G.

[0039] In some embodiments, base editing activity is assessed by editing efficiency. Base editing efficiency can be measured by any suitable means, for example, by Sanger sequencing or next-generation sequencing. In some embodiments, base editing efficiency is measured by the percentage of total sequencing reads with nuclear base conversions affected by the base editor, for example, the percentage of total sequencing reads with target C·G base pairs converted to A·T base pairs. In some embodiments, when base editing is performed in a cell population, base editing efficiency is measured by the percentage of total cells with nuclear base conversions affected by the base editor.

[0040] As used herein, the term "base editor system" refers to a system for editing a nucleobase of a target nucleotide sequence. In various embodiments, the base editor system comprises (1) a nucleic acid programmable nucleotide binding domain (e.g., Cas9); (2) a deaminase domain (e.g., adenosine deaminase) for deaminating the nucleobase; and (3) one or more guide polynucleotides (e.g., guide RNA).

[0041] "Guide polynucleotide," "guide RNA," or "gRNA" refers to a polynucleotide that can specifically target a target sequence and can form a complex with a nucleic acid programmable nucleotide binding domain protein (e.g., Cas9). In one embodiment, the guide polynucleotide is a guide RNA (gRNA). The gRNA can exist as a complex of two or more RNAs or as a single RNA molecule. A gRNA that exists as a single RNA molecule may be referred to as a single guide RNA (sgRNA), but "gRNA" is used interchangeably to refer to a guide RNA that exists as a single molecule or a complex of two or more molecules. Typically, a gRNA that exists as a single RNA species includes two domains: (1) a domain that has homology to the target nucleic acid (e.g., guides the binding of the Cas9 complex to the target nucleic acid); and (2) a domain that binds to the Cas9 protein. In some embodiments, domain (2) corresponds to a sequence called tracrRNA and includes a stem-loop structure. For example, in some embodiments, domain (2) is identical to or homologous to the tracrRNA provided in Jinek et al., Science 337:816-821 (2012). Other examples of gRNAs may be those disclosed in U.S. Provisional Patent Application USSN 61 / 874,682, filed on September 6, 2013, entitled “Switchable Cas9 Nucleases and Uses Thereof” and U.S. Provisional Patent Application USSN 61 / 874,746, filed on September 6, 2013, entitled “Delivery System For Functional Nucleases.” In some embodiments, the gRNA includes two or more of domains (1) and (2) and may be referred to as an “extended gRNA.” The extended gRNA will bind to two or more Cas9 proteins and bind to the target nucleic acid at two or more different regions. The gRNA includes a nucleotide sequence complementary to the target site that mediates the binding of the nuclease / RNA complex to the target site, providing sequence specificity for the nuclease:RNA complex.

[0042] According to the present invention, the amino acid three-letter code and the single-letter code used are as described in J.biol.chem, 243, p3558 (1968). "Vector" refers to a polynucleotide composition for transferring, delivering or introducing nucleic acid into a host cell. Suitable vectors include plasmid vectors, phage vectors, viral vectors (e.g., retroviral vectors, adeno-associated viral vectors, herpes simplex viral vectors, AAV vectors, lentiviral vectors, baculoviral vectors) and the like.

[0043] A "delivery system" comprises a delivery vehicle, which includes one or more liposomes, nanoparticles, exosomes, exosomes, microvesicles, viral vectors, gene guns or electroporation devices, etc.

[0044] "Functional fragment" means that the protein or polypeptide sequence includes fewer amino acids than the original sequence of the protein or polypeptide, but the remaining amino acid sequence still has a certain proportion (such as 10%, 20%, 30%, 40%, 50% or 60-99%, 100%) of functional activity relative to the functional activity of the original reference sequence (for example, the protein or polypeptide can be modified by substitution, insertion, deletion and / or addition of one or more amino acids while retaining a certain proportion of enzymatic activity).

[0045] "Identity" refers to the sequence matching between two polypeptides or two nucleic acids. When the positions in the two sequences being compared are occupied by the same base or amino acid monomer subunit (for example, if the position in each of the two DNA molecules is occupied by adenine, or the position in each of the two polypeptides is occupied by lysine), each molecule is identical at that position. "Percent identity" between two sequences is a function of the number of matching positions shared by the two sequences divided by the number of positions being compared and multiplied by 100. For example, if 6 out of 10 positions of the two sequences match, then the two sequences have 60% identity. For example, the DNA sequences CTGACT and CAGGTT have a total of 50% identity (3 out of a total of 6 positions match). Typically, comparison is performed when two sequences are aligned to produce maximum identity.

[0046] "Host cells" include in vitro, ex vivo or in vivo cells or cell lines or their progeny, including but not limited to CHO, BHK, 293, 293T cell lines, etc., wherein the cells or cell lines or their progeny contain: the Cas13 protein, fusion protein, CRISPR-Cas system, polynucleotide, vector or delivery system of the present invention.

[0047] "Operably linked" means that the nucleotide sequence of interest is linked to regulatory sequences in a manner that allows for expression of the nucleotide sequence (e.g., in an in vitro transcription / translation system or in a target cell when the vector is introduced into the target cell).

[0048] As used interchangeably herein, the terms "coding sequence" or "protein coding sequence" refer to a polynucleotide segment that encodes a protein. This region or sequence has a start codon near the 5' end and a stop codon near the 3' end. A coding sequence may also be referred to as an open reading frame.

[0049] The terms "nuclear localization sequence" and "nuclear localization signal (NLS)" refer to an amino acid sequence that promotes the import of proteins into the cell nucleus. Nuclear localization sequences are known in the art and are described, for example, in Plank et al., International PCT Application No. PCT / EP2000 / 011690, filed November 23, 2000, published as WO / 2001 / 038547 on May 31, 2001, the contents of which are incorporated herein by reference for their disclosure of exemplary nuclear localization sequences. In some embodiments, the NLS is an optimized NLS, such as described by Koblan et al., Nature Biotech. 2018 doi: 10.1038 / nbt.4172.

[0050] As used herein, the term "linker" may refer to a covalent linker (e.g., a covalent bond), a non-covalent linker, a chemical group, or a molecule connecting two molecules or parts (e.g., two components of a protein complex or a ribonucleic acid complex), for example, two domains of a fusion protein, such as a polynucleotide programmable DNA binding domain (e.g., dCas9) and a deaminase domain (e.g., adenosine deaminase). The linker can connect different components of a base editor system or different parts of a component. For example, in some embodiments, the linker can connect the guide polynucleotide binding domain of a polynucleotide programmable nucleotide binding domain and the catalytic domain of a deaminase. The linker can be located between or on both sides of two groups, molecules, or other parts and connected to each by a covalent bond or non-covalent interaction, thereby connecting the two. In some embodiments, the linker can be a polynucleotide. In some embodiments, the linker can be a DNA linker. In some embodiments, the linker can be an RNA linker.

[0051] In some embodiments, the joint can be an amino acid or multiple amino acids (for example, peptide or protein). In some embodiments, the length of the joint can be about 5 to 100 amino acids, for example, about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20 to 30, 30 to 40, 40 to 50, 50 to 60, 60 to 70, 70 to 80, 80 to 90 or 90 to 100 amino acid length. In certain embodiments, the length of the joint can be about 100 to 150, 150 to 200, 200 to 250, 250 to 300, 300 to 350, 350 to 400, 400 to 450 or 450 to 500 amino acids. Longer or shorter joints can also be considered.

[0052] As used herein, the term "cleavage" may refer to breaking the phosphodiester bond in a nucleotide chain. The type of break may be a single-strand break or a double-strand break.

[0053] As used in this disclosure, the terms "complementary" or "hybridization" are used to refer to "polynucleotides" and "oligonucleotides" (which are interchangeable terms referring to nucleotide sequences) in relation to the base pairing rules. For example, the sequence "CAGT" is complementary to the sequence "GTCA". Complementarity can be "partial" or "complete". "Partial" complementarity refers to one or more nucleic acid bases that are mismatched according to the base pairing rules, and "complete" or "complete" complementarity between nucleic acids refers to each nucleic acid base matching another base under the base pairing rules. The degree of complementarity between nucleic acid chains has an important influence on the efficiency and strength of hybridization between nucleic acid chains. This is particularly important in amplification reactions and detection methods that depend on binding between nucleic acids.

[0054] As used herein, the term "hybridization" refers to the pairing of complementary nucleic acids using any process whereby a nucleic acid strand binds to a complementary strand through base pairing to form a hybridization complex.

[0055] As used in the present disclosure, the terms "nucleic acid sequence" and "nucleotide sequence" refer to oligonucleotides or polynucleotides and fragments or portions thereof, and refer to DNA or RNA of genomic or synthetic origin that can be single-stranded or double-stranded, and represent sense or antisense strands. As used in the present disclosure, the terms "sequence identity" and "percentage of identity" refer to the percentage of nucleotides or amino acids that are identical (i.e., identical) between two or more polynucleotides or polypeptides. The sequence identity between two or more polynucleotides or polypeptides can be determined by the following method: the nucleotide or amino acid sequences of the polynucleotides or polypeptides are aligned and the number of positions containing the same nucleotides or amino acid residues in the aligned polynucleotides or polypeptides is scored, and compared with the number of positions containing different nucleotides or amino acid residues in the aligned polynucleotides or polypeptides. A polynucleotide can differ at one position, for example, by containing different nucleotides (i.e., substitutions or mutations) or missing nucleotides (i.e., nucleotide insertions or nucleotide deletions in one or two polynucleotides). A polypeptide can differ at one position, for example, by containing different amino acids (i.e., substitutions or mutations) or missing amino acids (i.e., amino acid insertions or amino acid deletions in one or two polypeptides). Sequence identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residue by the total number of amino acid residues in the polynucleotide or polypeptide. For example, percent identity can be calculated by dividing the number of positions containing the same nucleotide or amino acid residue by the total number of nucleotide or amino acid residues in the polynucleotide or polypeptide and multiplying by 100.

[0056] Exemplary, two or more sequences or subsequences have at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% nucleotide "sequence identity" or "percent identity" when compared and aligned for maximum correspondence using a sequence comparison algorithm or as measured by visual inspection. In certain embodiments, the sequences are substantially identical over the entire length of either or both compared biopolymers (e.g., polynucleotides).

[0057] The term "vector" refers to a means for introducing a nucleic acid sequence into a cell to produce a transformed cell. Vectors include plasmids, transposons, phages, viruses, liposomes, and episomes. An "expression vector" is a nucleic acid sequence that contains a nucleotide sequence to be expressed in a recipient cell. An expression vector may include additional nucleic acid sequences to facilitate and / or promote expression of the introduced sequence, such as initiation, termination, enhancer, promoter, and secretion sequences.

[0058] As used herein, the terms "individual" and "subject" are used interchangeably and refer to mammals. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In particular, the individual is a human.

[0059] The methods disclosed herein can be performed in vitro, ex vivo, or in vivo, or the products can exist in an in vitro, ex vivo, or in vivo form. The term "in vitro" refers to experiments using materials, biological substances, cells and / or tissues under laboratory conditions or in culture medium; while the term "in vivo" refers to experiments and procedures using intact multicellular organisms. In some embodiments, the methods performed in vivo can be performed on non-human animals. "Ex vivo" refers to an event that exists or occurs outside an organism, such as outside a human or animal, such as an event that can exist or occur on a tissue (e.g., a whole organ) or cell taken from an organism.

[0060] As used herein, the term "pharmaceutically acceptable carrier" refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., a lubricant, talc, magnesium stearate, calcium or zinc or stearic acid), or solvent encapsulating material, involved in transporting or transporting a compound from one part of the body (e.g., a delivery site) to another part (e.g., an organ, tissue, or part of the body). A pharmaceutically acceptable carrier is "acceptable" in the sense that it is compatible with the other ingredients of the formulation and is not harmful to the tissues of the subject (e.g., physiologically compatible, sterile, physiological pH, etc.). Some examples of materials that can serve as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, methylcellulose, ethylcellulose, microcrystalline cellulose, and cellulose acetate; (4) powdered tragacanth; (5) malt; (6) gelatin; (7) lubricants, such as magnesium stearate, sodium lauryl sulfate, and talc; (8) excipients, such as cocoa butter and suppository waxes; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, and treacle oil. oil, olive oil, corn oil, and soybean oil; (10) glycols, such as propylene glycol; (11) polyols, such as glycerol, sorbitol, mannitol, and polyethylene glycol (PEG); (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) pH buffered solutions; (21) polyesters, polycarbonates, and / or polyanhydrides; (22) bulking agents, such as peptides and amino acids; (23) serum components, such as serum albumin, high-density lipoprotein (HDL), and low-density lipoprotein (LDL); (22) C2-C12 alcohols, such as ethanol; and (23) other non-toxic compatible substances used in pharmaceutical formulations. Wetting agents, coloring agents, release agents, coating agents, sweeteners, flavoring agents, fragrances, preservatives, and antioxidants may also be present in the formulation.Terms such as "excipient," "pharmaceutically acceptable carrier," and the like are used interchangeably herein.

[0061] As used herein, the term "effective amount" refers to the amount of a bioactive agent sufficient to elicit a desired biological response. For example, in some embodiments, an effective amount of a base editor may refer to an amount of a base editor sufficient to induce a mutation in a target site specifically bound by a base editor mutation. As will be appreciated by those skilled in the art, the effective amount of an agent, such as a base editor fusion protein, a deaminase, a polynucleotide, etc., may vary with various factors, such as the desired biological response, such as the specific allele, genome, or target site to be edited, the targeted cell or tissue, and the agent used.

[0062] The terms "treatment", "processing" refer to a clinical intervention intended to reverse, alleviate a disease or disorder or one or more symptoms thereof, delay the onset of a disease or disorder or one or more symptoms thereof, or suppress the progression of a disease or disorder or one or more symptoms thereof as described herein. As used herein, the terms "treatment", "processing" refer to a clinical intervention intended to reverse, alleviate a disease or disorder or one or more symptoms thereof, delay the onset of a disease or disorder or one or more symptoms thereof, or suppress the progression of a disease or disorder or one or more symptoms thereof as described herein. In some embodiments, treatment can be administered after one or more symptoms have been formed and / or after the disease has been diagnosed. In other embodiments, treatment can be administered in the absence of symptoms, for example, for preventing or delaying the onset of symptoms or suppressing the onset or progression of a disease. For example, treatment can be administered to susceptible individuals before the onset of symptoms (for example, in view of the history of symptoms and / or in view of genetic or other susceptibility factors). Treatment can also be continued after the symptoms subside, for example to prevent or delay their recurrence.

[0063] Specifically, the present invention includes the following contents:

[0064] <Adenosine deaminase>

[0065] In some embodiments of the first aspect of the present invention, an adenosine deaminase is provided, comprising one or more of the following sequences:

[0066] An adenosine deaminase having an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 170, and which retains the deamination activity of the amino acid sequence shown in SEQ ID NO: 1;

[0067] An amino acid sequence in which one or more amino acid residues are added, substituted, deleted, or inserted into the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 170, and which retains the deamination activity of the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 170; or

[0068] An amino acid sequence encoded by a nucleotide sequence, which hybridizes to a polynucleotide sequence encoding the amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 170 under stringent conditions, and the amino acid sequence retains the deamination activity of the amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 170, wherein the stringent conditions are moderately stringent conditions, medium-high stringency conditions, high stringency conditions or very high stringency conditions.

[0069] The present invention also relates to a variant of adenosine deaminase, wherein the adenosine deaminase variant has changes in any of the following amino acid positions relative to the amino acid sequence shown in SEQ ID NO: 1: 33, 35, 36, 46, 47, 48, 49, 104, 105, 107, 148, 149, 150, 151, 152, 153, 154, 155.

[0070] Furthermore, the deaminase variant comprises a change in at least one amino acid position selected from the group consisting of V33I, D35G, D35R, D36N, D36G, A46C, I47Y, I47R, I47V, T48G, T48R, L49T, L49H, L49K, V104A, V104M, S105C, S105G, S107R, S107K, S107A, Q148, P, Q148C, Q148A, Q148G, Q149M, Q149G, Q149L, P150R, P150L, ​​P150C, R151K, E152R, E152T, E152G, E152W, V153P, V153F, V153I, V153T, F154H, F154K, F154L, N155T, N155R, N155H. The specific position changes can be combined in one or more. Specifically, the adenosine deaminase variant comprises any one of the following groups of changes relative to the amino acid sequence shown in SEQ ID NO: 1:

[0071] (1)Q148G+Q149M+P150R; (2)S107A; (3)E152R+V153P+F154H+N155T; (4)S107K; (5)Q148P+Q149G+P150L; (6)A46C+I47Y+T48G+L4 9H; (7)E152T+V153F+N155T; (8)S107R; (9)V104M; (10)E152G+V153I+F154K+N155R; (11)S105C; (12)Q148C+Q149L+P150R+R151K; (13)Q148A+Q149G+P150C; (14)E152W+V153T+F154L+N155H; (15)S105G; (16)I47R+T 48G+L49T; (17)D35G+D36N; (18)V33I+D35R+D36G; (19)V104A; (20)I47V+T48R+L49K.

[0072] The present invention provides an adenosine deaminase variant, wherein the adenosine deaminase variant has changes in any number of amino acid positions relative to the amino acid sequence shown in SEQ ID NO: 170. In some embodiments, the substitutions are substitutions at one or more of the following positions in the amino acid sequence shown in SEQ ID NO: 170:

[0073] S15, D16, H17, E18, F19, N20, D21, E22, Y23, W24, M25, R26, H27, A28, L29, T30, K33, R34, A35, R36 , V41, V43, L47, L49, N51, N59, A61, I62, L64, A69, E72, G80, L81, V82, L83, Q84, N85, Y86, I89, D9 0. A91, T92, V95, F97, A106, R111, I112, S113, R114, L115, F117, V119, R120, N121, S122, K123, R 124, N132, V133, L134, N135, P137, G138, M139, N140, H141, R142, E144, D160, V168, F169, N170.

[0074] Furthermore, in some embodiments, the substitution is a substitution occurring at one or more of the following positions in the amino acid sequence as shown in SEQ ID NO: 170:

[0075] S15T, S15G, D16E, D16N, H17C, H17K, E18D, E18K, F19C, F19Y, F19S, N20Q, N20L, N20S, D21Q, E22D, Y23F, W24F, M25L, M25V, R26K , R26T, H27R, A28C, L29I, T30E, K33R, K33S, R34K, A35S, R36Q, L49F, N51G, L64M, L64Q, L64P, G80A, L81N, V82A, V82T, L83I, L83 Q, Q84N, N85S, Y86W, I89E, I89L, D90G, A91C, A91T, T92D, A106C, I112L, S113K, R114K, V119L, S122N, S122P, R124H, R124T, N13 2K, V133I, L134F, N135H, N135S, P137F, G138A, M139L, N140K, H141A, R142L, R142S, E144H, D160E, V168A, F169C, F169V, N170D.

[0076] In some specific embodiments, the substitution is a combination of the following positions in the amino acid sequence as shown in SEQ ID NO: 170:

[0077] (1) S15T+D16E+H17K+F19Y+N20Q (adenosine deaminase 004V2);

[0078] (2) E22D+Y23F+W24F+R26K+H27R+L29I (adenosine deaminase 004V3);

[0079] (3) K33R+R34K+A35S (adenosine deaminase 004V4);

[0080] (4) G80A+L81N+V82A+L83I+Q84N+N85S+Y86W (adenosine deaminase 004V7);

[0081] (5) I89L+D90G+A91T+T92D (adenosine deaminase 004V8);

[0082] (6) I112L+S113K+R114K (adenosine deaminase 004V10);

[0083] (7) N132K+V133I+L134F+N135H (adenosine deaminase 004V12);

[0084] (8) P137F+G138A+M139L (adenosine deaminase 004V13);

[0085] (9) E18K+F19S+N20L (adenosine deaminase 004V14);

[0086] (10) M25L (adenosine deaminase 004V15);

[0087] (11) S15G+D16N+H17C (adenosine deaminase 004V16);

[0088] (12) L64Q+S122P+V168A (adenosine deaminase 004V17);

[0089] (13) R36Q+L64Q+S122P+F169V (adenosine deaminase 004V18);

[0090] (14) R36Q+V119L+V168A (adenosine deaminase 004V19);

[0091] (15) R36Q+V119L+N170D (adenosine deaminase 004V20);

[0092] (16) L64Q+V119L+V168A (adenosine deaminase 004V21);

[0093] (17) F169C (adenosine deaminase 004V22);

[0094] (18) L64Q+V119L+V168A (adenosine deaminase 004V23);

[0095] (19) L64P+R124T+F169V (adenosine deaminase 004V24);

[0096] (20) I89E+A91C (adenosine deaminase 004V25);

[0097] (21) L64Q+V119L+F169V (adenosine deaminase 004V26);

[0098] (22) L64M (adenosine deaminase 004V27);

[0099] (23) L64Q+S122P+N170D (adenosine deaminase 004V28);

[0100] (24) E18D+F19C+N20S (adenosine deaminase 004V29);

[0101] (25) L64P+V119L+N170D (adenosine deaminase 004V30);

[0102] (26) S122N+R124H+N135S+D160E (adenosine deaminase 004V31);

[0103] (27) R26T+H27R+A28C (adenosine deaminase 004V32);

[0104] (28) V82T+L83Q (adenosine deaminase 004V33);

[0105] (29) M25V (adenosine deaminase 004V34);

[0106] (30) D21Q+T30E+K33S (adenosine deaminase 004V35);

[0107] (31) N140K+H141A+R142S (adenosine deaminase 004V36);

[0108] (32) L49F+N51G (adenosine deaminase 004V37);

[0109] (33) A106C (adenosine deaminase 004V38);

[0110] (34) R142L+E144H (adenosine deaminase 004V39);

[0111] (35) E22R+Y23F+W24P+M25H (adenosine deaminase 004V40); and / or

[0112] (36)L64Q+R124T+V168A (adenosine deaminase 004V41).

[0113] In the present invention, the expression "retains deamination activity," for example, "retains the deamination activity of the amino acid sequence set forth in SEQ ID NO: 1" or "retains the deamination activity of the amino acid sequence set forth in SEQ ID NO: 170," can refer to an adenosine deaminase that completely retains the deamination activity of the original sequence, or can refer to an adenosine deaminase that partially retains the deamination activity of the original sequence, for example, retaining 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, or 99% of the deamination activity. In other embodiments, an adenosine deaminase having a modified sequence, for example, an adenosine deaminase having a sequence with amino acid substitutions, may also have a deamination activity higher than that of an adenosine deaminase having the original sequence.

[0114] The adenosine deaminase provided by the present invention can act on any polynucleotide, including DNA, RNA, and DNA-RNA hybrids. In certain embodiments, the adenosine deaminase can deaminate the target adenine (A) in a polynucleotide comprising DNA. In certain embodiments, the adenosine deaminase can deaminate the target adenine (A) in a polynucleotide comprising RNA. In some embodiments, the substitution is a conservative substitution.

[0115] As used herein, "moderately stringent conditions," "medium-high stringency conditions," "high stringency conditions," or "very high stringency conditions" describe conditions for nucleic acid hybridization and washing. Guidance for conducting hybridization reactions can be found in Current Protocols in Molecular Biology, John Wiley & Sons, NY (1989), 6.3.1-6.3.6, which is incorporated herein by reference. Both aqueous and nonaqueous methods are described in this document, and either method can be used. For example, specific hybridization conditions are as follows: (1) low stringency hybridization conditions are in 6× sodium chloride / sodium citrate (SSC) at about 45°C, followed by two washes in 0.2×SSC, 0.1% SDS at at least 50°C (the wash temperature can be increased to 55°C for low stringency conditions); (2) moderate stringency hybridization conditions are in 6×SSC at about 45°C, followed by one or more washes in 0.2×SSC, 0.1% SDS at 60°C; (3) high stringency hybridization conditions are in 6×SSC at about 45°C, followed by one or more washes in 0.2×SSC, 0.1% SDS at 65°C, and preferably; (4) very high stringency hybridization conditions are 0.5 M sodium phosphate, 7% SDS at 65°C, followed by one or more washes in 0.2×SSC, 1% SDS at 65°C.

[0116] The amino acid sequence of adenosine deaminase 005V1 is as follows:

[0117] The amino acid sequence of adenosine deaminase 004V1 is as follows;

[0118] The nucleotide sequence of adenosine deaminase 005V1 is as follows:

[0119] Nucleotide sequence of adenosine deaminase 004V1:

[0120] <Base editor fusion protein>

[0121] The second aspect of the present invention provides a base editor fusion protein, which comprises the adenosine deaminase described in the first aspect of the present invention and a nucleic acid programmable nucleotide binding domain.

[0122] In the present invention, the nucleic acid programmable nucleotide binding domain, when bound to a bound guide polynucleotide (e.g., gRNA), can specifically bind to a target polynucleotide sequence (i.e., by a complementary base pairing sequence between the bases of the bound guide nucleic acid and the bases of the target polynucleotide), thereby positioning the base editor to the target nucleic acid sequence that needs to be edited. In some embodiments, the target polynucleotide sequence comprises single-stranded DNA or double-stranded DNA. In some embodiments, the target polynucleotide sequence comprises RNA. In some embodiments, the target polynucleotide sequence comprises a DNA-RNA hybrid. It should be understood that the nucleic acid programmable nucleotide binding domain can also include a nucleic acid programmable protein that binds to RNA.

[0123] In some embodiments of the present invention, the nucleic acid programmable nucleotide binding domain in the base editor is a Cas protein or an AGO protein. The Cas protein or AGO protein includes a naturally occurring Cas protein or AGO protein, and a homolog thereof or a modified or engineered version thereof. For example, in some embodiments, the Cas protein or AGO protein may be a protein comprising an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identity with the amino acid sequence of a naturally occurring Cas protein or AGO protein. In other embodiments, the Cas protein also includes a protein in the form of a nickase or nuclease-inactive form thereof.

[0124] In some embodiments, non-limiting examples of Cas proteins that can serve as nucleic acid-programmable nucleotide binding domains include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas8a, Cas8b, Cas8c, Cas9 (also known as Csn1 or Csx12), Cas10, Cas10d, Cas12a / Cpfl, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12f (C2c10 / Cas14), Cas12g, Cas12h, Cas12i, Cas12j, Cas12k / C2c5, Cas12l, Cas12m, Cas12n, Cas13a (C2c2), Cas13b (C2c3), Cas13c (C2c4), Cas13d (C2c5), Cas13e (C2c6), Cas13f (C2c7), Cas13f (C2c8), Cas13f (C2c9), Cas13f (C2c10), Cas13f (C2c11), Cas13f (C2c12), Cas13f (C2c13), Cas13f (C2c14), Cas13f (C2c15), Cas13f (C2c16), Cas13f (C2c17), Cas13f (C2c18), Cas13f (C2c19), Cas13f (C2c20), Cas13f (C2c19), Cas13f (C2c11), Cas13f (C2c12), Cas13f ( 13b, Cas13c, Cas13d, Csy1, Csy2, Csy3, Csy4, Css1, Css2, Cse5e, Csc2, Csa5, Csn1, Csn2, Csm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr2, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx1 4, Csx10, Csx16, Csx1, Csx1S, Csx11, Csf1, Csf2, CsO, Csf4, Csd1, Csd2, Cst1, Cst2, Csh1, Csh2, Csa1, Csa2, Csa3, Csa4, Csa5, class II Cas effector proteins, type V Cas effector proteins, class VI Cas proteins, CARF, DinG, homologs thereof, or modified or engineered versions thereof. Other nucleic acid programmable nucleotide binding domains are also within the scope of the present disclosure, although they may not be specifically listed in the present disclosure.

[0125] In some specific embodiments of the present invention, the Cas protein is selected from the Cas9 family, the Cas12 family and the Cas13 family, such as but not limited to Cas9, Cas12a (Cpf1), Cas12b (C2c1), Cas12c (C2c3), Cas12d (CasY), Cas12e (CasX), Cas12f (C2c10 / Cas14), Cas12g, Cas12h, Cas12i, Cas12j, Cas12k (C2c5), Cas12l, Cas12m, Cas12n, Cas13a (C2c2), Cas13b, Cas13c, Cas13d, homologs thereof, or modified or engineered versions thereof. In some specific embodiments of the present invention, the Cas protein includes a nuclease-free form of the above-mentioned Cas protein, such as dCas9, dCas12a, dCas12b, dCas12c, dCas12d, dCas12e, dCas12f, dCas12g, dCas12h, dCas12i, dCas12j, dCas12k, dCas12l, dCas12m, dCas12n, dCas13a, dcas13b, dCas13c and dCas13d. In some specific embodiments of the present invention, the Cas protein also includes a nickase form of the above-mentioned protein, such as nCas9, but not limited to nCas9.

[0126] In some preferred embodiments of the present invention, the nucleic acid programmable nucleotide binding domain is Cas9. In some specific embodiments of the present invention, Cas9 is Cas9 from Streptococcus pyogenes (SpCas9), Cas9 from Staphylococcus aureus (SaCas9), or Cas9 from Streptococcus thermophilus 1 (St1Cas9). In some preferred embodiments of the present invention, Cas9 is Cas9 from Streptococcus pyogenes (SpCas9).

[0127] In some more preferred embodiments of the present invention, Cas9 can be nuclease-active Cas9, Cas9 nickase (nCas9) or nuclease-inactive Cas9 (dCas9).

[0128] In some further preferred embodiments of the present invention, the nucleic acid programmable nucleotide binding domain is a Cas9 nickase (nCas9). In some other further preferred embodiments of the present invention, the nucleic acid programmable nucleotide binding domain comprises an amino acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identity to the amino acid sequence of the Cas9 nickase (nCas9) provided herein. In some embodiments of the present invention, adenosine deaminase is directly fused / connected to the nucleic acid programmable nucleotide binding domain to form a fusion protein, or is fused / connected to form a fusion protein through a linker. There is no particular restriction on the fusion / connection order of adenosine deaminase and nucleic acid programmable nucleotide, for example, adenosine deaminase can be at the N-terminus of the base editor, or the nucleic acid programmable nucleotide binding domain is located at the N-terminus of the base editor.

[0129] In embodiments where adenosine deaminase is directly fused to a nucleic acid programmable nucleotide binding domain, an exemplary base editor fusion protein has the following structure:

[0130] NH2-[adenosine deaminase]-[napDNAbp]-COOH;

[0131] NH2-[napDNAbp]-[adenosine deaminase]-COOH; or

[0132] NH2-[N-terminal fragment of napDNAbp]-[adenosine deaminase]-[C-terminal fragment of napDNAbp]-COOH.

[0133] In embodiments where adenosine deaminase is fused to a nucleic acid programmable nucleotide binding domain via a linker, an exemplary base editor fusion protein has the following structure:

[0134] NH2-[adenosine deaminase]-[optional linker]-[napDNAbp]-COOH;

[0135] NH2-[napDNAbp]-[optional linker]-[adenosine deaminase]-COOH; or

[0136] NH2-[N-terminal fragment of napDNAbp]-[optional linker]-[adenosine deaminase]-[optional linker]-[C-terminal fragment of napDNAbp]-COOH.

[0137] In some embodiments, the domain of a nucleobase editor is fused via a linker comprising the following amino acid sequence:

[0138] In some embodiments of the present invention, the base editor further includes at least one nuclear localization signal sequence (NLS sequence), and the NLS sequence can be selected from the amino acid sequences in the following table:

[0139] In some embodiments of the present invention, the nuclear localization signal sequence can be located at the N-terminus, C-terminus, or both ends of the base editor, or between the adenosine deaminase and the nucleic acid programmable nucleotide binding domain. In some embodiments of the present invention, the nuclear localization signal sequence can be directly fused to the base editor or fused to the base editor through a linker.

[0140] An exemplary structure of a base editor comprising a nuclear localization signal sequence is as follows:

[0141] NH2-[NLS]-[adenosine deaminase]-[napDNAbp]-COOH;

[0142] NH2-[adenosine deaminase]-[NLS]-[napDNAbp]-COOH;

[0143] NH2-[adenosine deaminase]-[napDNAbp]-[NLS]-COOH;

[0144] NH2-[NLS]-[napDNAbp]-[adenosine deaminase]-COOH;

[0145] NH2-[napDNAbp]-[NLS]-[adenosine deaminase]-COOH;

[0146] NH2-[napDNAbp]-[adenosine deaminase]-[NLS]-COOH;

[0147] NH2-[NLS]-[adenosine deaminase]-[optional linker]-[napDNAbp]-COOH;

[0148] NH2-[adenosine deaminase]-[optional linker]-[NLS]-[optional linker]-[napDNAbp]-COOH;

[0149] NH2-[adenosine deaminase]-[optional linker]-[napDNAbp]-[NLS]-COOH;

[0150] NH2-[NLS]-[napDNAbp]-[optional linker]-[adenosine deaminase]-COOH;

[0151] NH2-[napDNAbp]-[optional linker]-[NLS]-[optional linker]-[adenosine deaminase]-COOH;

[0152] NH2-[napDNAbp]-[optional linker]-[adenosine deaminase]-[NLS]-COOH;

[0153] NH2-[NLS]-[Adenosine deaminase]-[Optional linker]-[napDNAbp]-[NLS]-COOH.

[0154] In some preferred embodiments of the present invention, the base editor has the following structure:

[0155] NH2-[NLS]-[adenosine deaminase]-[optional linker]-[napDNAbp]-[NLS]-COOH; or

[0156] NH2-[NLS]-[N-terminal fragment of napDNAbp]-[optional linker]-[adenosine deaminase]-[optional linker]-[C-terminal fragment of napDNAbp]-[NLS]-COOH.

[0157] In some further preferred embodiments of the present invention, the base editor comprises one or more of the following sequences:

[0158] (i) the amino acid sequence shown in SEQ ID NO: 190 or SEQ ID NO: 3;

[0159] (ii) an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 190 or SEQ ID NO: 3, and which retains the polynucleotide binding and base editing activity of the amino acid sequence set forth in SEQ ID NO: 190 or SEQ ID NO: 3;

[0160] (iii) an amino acid sequence in which one or more amino acid residues are added, substituted, deleted, or inserted into the amino acid sequence of SEQ ID NO: 190 or SEQ ID NO: 3, and which retains the polynucleotide binding and base editing activity of the amino acid sequence of SEQ ID NO: 190 or SEQ ID NO: 3; or

[0161] (iv) an amino acid sequence encoded by a nucleotide sequence that hybridizes to a polynucleotide sequence encoding the amino acid sequence as shown in SEQ ID NO: 190 or SEQ ID NO: 3 under stringent conditions, and the amino acid sequence retains the binding polynucleotide and base editing activity of the amino acid sequence as shown in SEQ ID NO: 190 or SEQ ID NO: 3, wherein the stringent conditions are medium stringency conditions, medium-high stringency conditions, high stringency conditions or very high stringency conditions.

[0162] The base editor sequences composed of adenosine deaminase 004V1 and 005V1 and nCas9 are as follows:

[0163] Amino acid sequence of 004V1-nCas9:

[0164] Among them, the bold sequence represents the sequence derived from nCas9; the italic represents the linker sequence; the double-underlined sequence represents the nuclear localization sequence; the single-underlined sequence is the deaminase 004V1 sequence; the asterisk at the C-terminus represents the stop codon position.

[0165] 005V1-nCas9 amino acid sequence:

[0166] Among them, the bold sequence represents the sequence derived from nCas9, the italic represents the linker sequence, the double-underlined sequence represents the nuclear localization sequence; the single-underlined sequence is the adenosine deaminase 005V1 sequence, and the asterisk represents the position of the stop codon.

[0167] The nucleotide sequence of 005V1-nCas9 is shown below:

[0168] Furthermore, the present invention also provides mutants obtained by amino acid substitution based on adenosine deaminase 004V1: adenosine deaminase 004V2, adenosine deaminase 004V3, adenosine deaminase 004V4, adenosine deaminase 004V7, adenosine deaminase 004V8, adenosine deaminase 004V10, adenosine deaminase 004V12, and adenosine deaminase 004V13-004V41, specifically as follows:

[0169] The exemplary sequences of the base editors composed of the above-mentioned adenosine deaminases are as follows:

[0170] The amino acid sequence of 004V2-nCas9 is shown below:

[0171] Among them, the bold sequence represents the sequence derived from nCas9, the italic represents the linker sequence, the double-underlined sequence represents the nuclear localization sequence; the single-underlined sequence is the adenosine deaminase 004V2 sequence, and the asterisk represents the position of the stop codon.

[0172] The amino acid sequence of 004V3-nCas9 is shown below:

[0173] Among them, the bold sequence represents the sequence derived from nCas9, the italic represents the linker sequence, the double-underlined sequence represents the nuclear localization sequence; the single-underlined sequence is the deaminase 004V3 sequence, and the asterisk represents the position of the stop codon.

[0174] The amino acid sequence of 004V4-nCas9 is shown below:

[0175] Among them, the bold sequence represents the sequence derived from nCas9, the italic represents the linker sequence, the double-underlined sequence represents the nuclear localization sequence; the single-underlined sequence is the deaminase 004V4 sequence, and the asterisk represents the position of the stop codon.

[0176] The amino acid sequence of 004V7-nCas9 is shown below:

[0177] Among them, the bold sequence represents the sequence derived from nCas9, the italic represents the linker sequence, the double-underlined sequence represents the nuclear localization sequence; the single-underlined sequence is the deaminase 004V7 sequence, and the asterisk represents the position of the stop codon.

[0178] The amino acid sequence of 004V8-nCas9 is shown below:

[0179] Among them, the bold sequence represents the sequence derived from nCas9, the italic represents the linker sequence, the double-underlined sequence represents the nuclear localization sequence; the single-underlined sequence is the deaminase 004V8 sequence, and the asterisk represents the position of the stop codon.

[0180] The amino acid sequence of 004V10-nCas9 is shown below:

[0181] Among them, the bold sequence represents the sequence derived from nCas9, the italic represents the linker sequence, the double-underlined sequence represents the nuclear localization sequence; the single-underlined sequence is the deaminase 004V10 sequence, and the asterisk represents the position of the stop codon.

[0182] The amino acid sequence of 004V12-nCas9 is shown below:

[0183] Among them, the bold sequence represents the sequence derived from nCas9, the italic represents the linker sequence, the double-underlined sequence represents the nuclear localization sequence; the single-underlined sequence is the deaminase 004V12 sequence, and the asterisk represents the position of the stop codon.

[0184] The amino acid sequence of 004V13-nCas9 is shown below:

[0185] Among them, the bold sequence represents the sequence derived from nCas9; the italic represents the linker sequence; the double-underlined sequence represents the nuclear localization sequence; the single-underlined sequence is the adenosine deaminase 004V13 sequence; the asterisk at the C-terminus represents the stop codon position.

[0186] Furthermore, the present invention also provides mutants obtained by performing amino acid substitution at one or more sites based on adenosine deaminase 005V1, including deaminase 005V1-10-3, 005V1-11-5, 005V1-10-1, 005V1-11-2, 005V1-15-1, 005V1-11-3, 005V1-10-4, 005V1-11-4, 005V1-15-2, 005V1-2-7, 005V1-1-1, 005V1-1-2, 005 V1-1-3, 005V1-1-4, 005V1-1-5, 005V1-1-6, 005V1-1-7, 005V1-1-8, 005V1-2-1, 005V1-2-2, 005V1-2-3, 005V1- 2-5, 005V1-2-6, 005V1-2-8, 005V1-3-1, 005V1-3-2, 005V1-3-3, 005V1-3-4, 005V1-3-5, 005V1-3-7, 005V1-3-8 , 005V1-4-1, 005V1-4-2, 005V1-4-3, 005V1-15-5, 005V1-5-4, 005V1-5-8, 005V1-10-5, 005V1-5-2, 005V1-3-6, 005V1-4-5, 005V1-4-7, 005V1-4-8, 005V1-5-1, 005V1-5-3, 005V1-5-5, 005V1-5-6, 005V1-5-7, 005V1-6-1, 005 There are many mutants including 005V1-6-2, 005V1-6-5, 005V1-6-6, 005V1-6-8, 005V1-7-1, 005V1-7-2, 005V1-7-3, 005V1-8-1, 005V1-8-2, 005V1-8-3, 005V1-8-4, 005V1-8-5, 005V1-9-1, 005V1-9-2, 005V1-9-3, 005V1-9-4, 005V1-9-5, and 005V1-10-2.

[0187] By searching for a suitable insertion site for adenosine deaminase in the middle of the nCas9 protein, a variety of chimeric base editor fusion proteins with improved editing efficiency were obtained. The adenosine deaminases used include adenosine deaminase 005V1, 005V1-10-1, and 005V1-10-3. The above three adenosine deaminase sequences are base editor fusion proteins. The nucleic acid programmable nucleotide binding domain selects the nCas9 domain. The insertion position of the adenosine deaminase is between amino acid positions 583-584, 768-769, 770-771, 776-777, 793-794, 905-906, 919-920, 1048-1063, 1049-1062, 1249-1250, 1263-1264, or 1276-1277 of SEQ ID NO: 61.

[0188] In the present invention, "retaining the binding polynucleotide and base editing activity of the amino acid sequence as shown in SEQ ID NO: 190" and "retaining the binding polynucleotide and base editing activity of the amino acid sequence as shown in SEQ ID NO: 3" can be completely retaining the binding polynucleotide and base editing activity of the base editor with the amino acid sequence as shown in SEQ ID NO: 190 or SEQ ID NO: 3, or it can be partially retaining its activity. In other embodiments, the base editor with a modified sequence may also have higher binding polynucleotide and base editing activity than the base editor with the amino acid sequence as shown in SEQ ID NO: 190 or SEQ ID NO: 3.

[0189] It should be understood that the base editor fusion protein of the present disclosure may include one or more additional features. For example, in some embodiments, the fusion protein may include inhibitors, cytoplasmic localization sequences, export sequences, such as nuclear export sequences or other localization sequences, and tags that can be used for dissolving, purifying or detecting fusions. Suitable tags provided herein include, but are not limited to, biotin carboxylase carrier protein (BCCP) tags, myc tags, calmodulin tags, FLAG tags, hemagglutinin (HA) tags, polyhistidine tags, also known as histidine tags or His- tags, maltose binding protein (MBP) - Tags, nus- tags, glutathione-S-transferase (GST) - tags, green fluorescent protein (GFP) - tags, thioredoxin - tags, S- tags, Softags (e.g., Softag 1, Softag 3), chain tags, biotin ligase tags, Flash tags, V5 tags and SBP tags. Other suitable sequences are apparent to those skilled in the art. In some embodiments, the fusion protein includes one or more His tags.

[0190] <Polynucleotide>

[0191] The third aspect of the present invention provides a polynucleotide encoding the adenosine deaminase described in the first aspect of the present invention or encoding the base editor fusion protein described in the second aspect of the present invention.

[0192] <Expression vector>

[0193] The fourth aspect of the present invention provides a vector comprising the polynucleotide of the third aspect of the present invention. In some embodiments of the present invention, the vector is a mammalian expression vector. In some embodiments, the expression vector is selected from one or more of an adeno-associated virus, a retroviral vector, an adenoviral vector, a lentiviral vector, a Sendai virus vector, and a herpes virus vector. In some embodiments, the vector comprises a promoter.

[0194] <Cell>

[0195] The fifth aspect of the present invention provides a cell comprising one or more of the adenosine deaminase described in the first aspect of the present invention, the base editor fusion protein described in the second aspect of the present invention, the polynucleotide described in the third aspect of the present invention, and the vector described in the fourth aspect of the present invention. In some embodiments of the present invention, the cell is a prokaryotic cell, a eukaryotic cell, and further, may be a bacterial cell, a plant cell, an insect cell, a human cell, or a mammalian cell.

[0196] <Base Editor System>

[0197] The sixth aspect of the present invention provides a base editor system. In some embodiments, the base editor system comprises the adenosine deaminase described in the first aspect of the present invention, a nucleic acid programmable nucleotide binding domain, and a guide polynucleotide. In other embodiments, the base editor system comprises the base editor fusion protein described in the second aspect of the present invention, and a guide polynucleotide.

[0198] In some embodiments of the present invention, the guide polynucleotide is a guide RNA (gRNA), which is a short synthetic RNA consisting of a backbone sequence required for Cas protein binding and a user-defined spacer sequence of about 20 nucleotides that defines the genomic target to be modified. Thus, a technician can change the genomic target specificity of the Cas protein depending in part on the specificity of the gRNA targeting sequence for the genomic target compared to the rest of the genome.

[0199] In some more specific embodiments of the present invention, the guide polynucleotide is an sgRNA, which consists of a backbone sequence required for Cas protein binding and a user-defined spacer sequence of about 20 nucleotides.

[0200] Different backbone sequences can be selected for Cas proteins of different sources or types. In some more specific embodiments of the present invention, the backbone sequence of the domain (SpCas9) binding to the Cas9 protein, i.e., the sgRNA, is:

[0201] <Pharmaceutical Compositions, Kits, Delivery Systems, Uses, and Methods>

[0202] The seventh aspect of the present invention provides a pharmaceutical composition, which comprises one or more of the adenosine deaminase described in the first aspect of the invention, the base editor fusion protein described in the second aspect of the invention, the polynucleotide described in the third aspect of the invention, the expression vector described in the fourth aspect of the invention, the cell described in the fifth aspect of the invention, and the base editor system described in the sixth aspect of the invention, and a pharmaceutically acceptable carrier.

[0203] In some embodiments, the pharmaceutically acceptable carrier can be a delivery carrier, such as a lipid, a cationic lipid, or other polymers with drug delivery function.

[0204] The eighth aspect of the present invention provides a kit, specifically a disease treatment kit, which comprises the adenosine deaminase described in the first aspect of the present invention, the base editor fusion protein described in the second aspect of the present invention, the polynucleotide described in the third aspect of the present invention, the expression vector described in the fourth aspect of the present invention, the cell described in the fifth aspect of the present invention, the base editor system described in the sixth aspect of the present invention and one or more of the pharmaceutical composition described in the seventh aspect of the present invention.

[0205] The ninth aspect of the present invention provides a delivery system comprising one or more of the adenosine deaminase described in the first aspect of the present invention, the base editor fusion protein described in the second aspect of the present invention, the polynucleotide described in the third aspect of the present invention, the vector described in the fourth aspect of the present invention, the cell described in the fifth aspect of the present invention, and the base editor system described in the sixth aspect of the present invention, and a delivery medium.

[0206] In some embodiments, the delivery medium can be nanoparticles, liposomes, exosomes, microvesicles, a gene gun, a cell-penetrating peptide, or the like.

[0207] The tenth aspect of the present invention provides the use of the adenosine deaminase described in the first aspect of the present invention in the preparation of a base editor or a base editor system.

[0208] The eleventh aspect of the present invention provides the use of the adenosine deaminase described in the first aspect of the present invention, the base editor fusion protein described in the second aspect of the present invention, the polynucleotide described in the third aspect of the present invention, the expression vector described in the fourth aspect of the present invention, the cell described in the fifth aspect of the present invention, the base editor system described in the sixth aspect of the present invention or the pharmaceutical composition described in the seventh aspect of the present invention, and the delivery system described in the ninth aspect of the present invention in the preparation of a medicament for treating diseases associated with or caused by point mutations.

[0209] In some embodiments, the drug can correct the point mutation. In some embodiments, the point mutation is G to A and / or C to T.

[0210] In some embodiments, the diseases associated with or caused by point mutations include hypercholesterolemia, transthyretin amyloidosis, and beta-hemoglobinopathy; in other embodiments, non-limiting examples of the diseases include Meier-Gorlin syndrome; Seckel syndrome; Joubert syndrome; Leber congenital amaurosis; Charcot-Marie-Tooth disease, type 2; Charcot-Marie-Tooth disease, type 2; Usher syndrome, type 2C; spinocerebellar ataxia; long QT syndrome 2; Theograin-Larsson syndrome. syndrome; hereditary leukodystrophy; hereditary leukodystrophy; neuroblastoma; neuroblastoma; Kallmann syndrome 1; Kallmann syndrome; metachromatic leukodystrophy; Rett syndrome; amyotrophic lateral sclerosis type 10; Li-Fraumeni syndrome.

[0211] The twelfth aspect of the present invention provides a method for base editing of nucleic acid, which includes the step of contacting the nucleic acid with the base editor system described in the sixth aspect of the present invention.

[0212] In some embodiments, the nucleic acid is DNA. Further, the nucleic acid is double-stranded DNA.

[0213] In some embodiments, the nucleic acid comprises a target sequence associated with a disease.

[0214] In some embodiments, the target sequence comprises a point mutation associated with a disease.

[0215] In some specific embodiments, the target sequence comprises a point mutation from G to A or C to T associated with a disease or condition, and wherein deamination of the mutated A base results in a sequence not associated with the disease or condition.

[0216] In some embodiments, the target sequence encodes a protein, and wherein the point mutation is in a codon and results in a change in the amino acid encoded by the mutated codon compared to the wild-type codon.

[0217] In some embodiments, the target sequence is located at a splice site, and wherein the point mutation results in an altered splicing of the mRNA transcript compared to a wild-type transcript.

[0218] In some embodiments, the target sequence is located at the promoter of a gene, and wherein the point mutation results in increased expression of the gene.

[0219] In some embodiments, the target sequence is located at the promoter of a gene, and wherein the point mutation results in decreased expression of the gene.

[0220] In some embodiments, the nucleic acid is located within the genome of an organism.

[0221] In some embodiments, the organism is a prokaryote or a eukaryote or a vertebrate or a mammal.

[0222] In some embodiments, deamination of the mutant A base results in a change in the amino acid encoded by the mutant codon, or results in a codon encoding a wild-type amino acid, or results in a change in the mRNA transcript, or results in a wild-type mRNA transcript, or results in increased gene expression, or results in decreased gene expression.

[0223] In some embodiments, the contacting is performed in vitro.

[0224] In some embodiments, the contacting is performed in vivo in a subject.

[0225] In some embodiments, the subject has been diagnosed with a disease or disorder.

[0226] In some embodiments, the disease or condition is associated with a point mutation in the proprotein convertase subtilisin / kexin type 9 (PCSK9) gene.

[0227] In some embodiments, the disease comprises hypercholesterolemia, transthyretin amyloidosis, beta-hemoglobinopathies. In other embodiments, the disease includes, but is not limited to, Meier-Gorlin syndrome; Seckel syndrome; Joubert syndrome; Leber congenital amaurosis; Charcot-Marie-Tooth disease, type 2; Charcot-Marie-Tooth disease, type 2; Usher syndrome, type 2C; spinocerebellar ataxia; long QT syndrome; Theograin-Larsson syndrome; hereditary diabetes mellitus; hereditary diabetes mellitus; neuroblastoma; neuroblastoma; Kallmann syndrome; metachromatic leukodystrophy; Rett syndrome; amyotrophic lateral sclerosis type 10; and Li-Fraumeni syndrome.

[0228] The thirteenth aspect of the present invention provides a method for treating a disease associated with or caused by a point mutation. In some embodiments, the provided method comprises administering to a subject suffering from such a disease an effective amount of the base editor fusion protein described in the second aspect of the present invention for correcting the point mutation or introducing an inactivating mutation into a disease-related gene, the base editor system described in the sixth aspect of the present invention, the pharmaceutical composition described in the seventh aspect of the present invention, the kit described in the eighth aspect of the present invention, or the delivery system described in the ninth aspect of the present invention.

[0229] <Comparison>

[0230] In the following examples, the efficient base editor ABE8e evolved by the David R. Liu team (Richter MF, Zhao KT, Eton E, Lapinaite A, Newby GA, Thuronyi BW, Wilson C, Koblan LW, Zeng J, Bauer DE, Doudna JA, Liu DR. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat Biotechnol. 2020 Jul; 38(7): 883-891. doi: 10.1038 / s41587-020-0453-z. Epub 2020 Mar 16. Erratum in: Nat Biotechnol. 2020 May 20;: PMID: 32433547; PMCID: PMC7357821.) For comparison, compared with the base editor comprising the adenosine deaminase provided by the present invention, ABE8e is based on ABE7.10 (Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, Liu DR. Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage. Nature. 2017 Nov 23; 551(7681): 464-471. doi: 10.1038 / nature24644. Epub 2017 Oct 25. Erratum in: Nature. 2018 May 2;: PMID: 29160308; PMCID: PMC5726555.) was obtained by optimizing the deaminase component of ABE7.10; according to the experimental results obtained by the aforementioned team, the activity (expressed as first-order kinetics.deamination rate constants, kapp) was increased 590 times compared with ABE7.10.

[0231] Specifically, in the following examples, the amino acid sequence of ABE8e is as follows:

[0232] Among them, the bold sequence represents the sequence derived from nCas9; the italic represents the linker sequence; the double-underlined sequence represents the nuclear localization sequence; the single-underlined sequence is the ecTadA* deaminase sequence; and the * at the end of the C-terminus indicates the position of the stop codon.

[0233] Accordingly, the nucleotide sequence of ABE8e is as follows:

[0234] In the following examples, ABE8e and the napDNAbp used in the base editor comprising the adenosine deaminase provided by the present invention are all nCas9, and its amino acid sequence is as follows:

[0235] The nucleotide sequence of nCas9 is as follows:

[0236] Advantageous Effects of the Invention

[0237] The present invention improves the editing efficiency of the corresponding base editor by performing site-directed mutagenesis on the parent adenosine deaminase, expands the application prospects, and has potential utilization value. The base editor involved in the present invention has a significantly higher editing efficiency at the PCSK9 target and other sites than the wild type, and has great potential in the treatment of diseases related to or caused by point mutations (such as hypercholesterolemia, transthyretin amyloidosis, and β-hemoglobinopathy). Through a lot of exploratory research, some adenosine deaminases and nucleases constitute base editors, and a suitable chimeric position suitable for the adenosine deaminase of the present invention inside the nCas9 protein has been found, further improving the base editing efficiency.

[0238] For any embodiment of the present invention described herein, including an embodiment described only in the examples or claims or described only in one aspect / section below, it should be understood that unless expressly denied or the combination is inappropriate, the embodiment can be combined with any other one or more embodiments of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS

[0239] Figure 1 is a map of the 005V1-nCas9 plasmid.

[0240] Figure 2 shows the editing efficiency of 005V1-nCas9 and various mutant base editors at the PCSK9 site. The editing target site is the PCSK9 gene, and the cells used are 293T cells.

[0241] Figure 3 is a comparison of the editing efficiency of 005V1-nCas9 and various mutant base editors at the PCSK9 site. In order to more clearly show the comparison of the editing efficiency of the mutant base editor and 005V1-nCas9, the editing efficiency value of 005V1-nCas9 is set to 1, and the editing efficiency of other mutant base editors is calculated proportionally.

[0242] Figure 4 is a comparison of the editing efficiency of mutant base editors with editing efficiency and 005V1-nCas9, including 005V1-10-3-nCas9, 005V1-10-1-nCas9, 005V1-11-2-nCas9, 005V1-15-1-nCas9, 005V1-11-3-nCas9, 005V1-11-5-nCas9, 005V1-10-4-nCas9, 005V1-11-4-nCas9, 005V1-15-2-n Comparison of the editing efficiency of base editors such as Cas9, 005V1-3-3-nCas9, 005V1-15-5-nCas9, 005V1-5-4-nCas9, 005V1-5-8-nCas9, 005V1-10-5-nCas9, 005V1-5-2-nCas9, 005V1-3-6-nCas9, 005V1-2-7-nCas9, and 005V1-nCas9. For ease of display, only the name of adenosine deaminase is marked in the figure to refer to the corresponding base editor.

[0243] Figure 5 compares the editing efficiency of 005V1-nCas9 and some mutant base editors at different sites. The different depths of color in the figure represent different editing efficiencies. For ease of display, only the name of adenosine deaminase is marked in the figure to refer to the corresponding base editor.

[0244] Figure 6A and Figure 6B are the PHK09 plasmid map (Figure 6A) and the 004V1-nCas9 structure diagram (Figure 6B), respectively.

[0245] Figure 7 shows the editing efficiency of 004V1-nCas9 from A·T to G·C at site 1, which includes A to C. Figure 7-A shows a comparison of the editing efficiency of 004V1-nCas9 and ABE8e at site 1. The editing positions are adenine deoxynucleotides +3, +5, +7, and +8 from the 5' end of the sgRNA. The error bars represent the mean ± SEM, and there are 3 biological replicates for each group of samples. Figure 7-B shows the sequencing results at site 1 after transfection of the base editor 004V1-nCas9; Figure 7-C shows the sequencing results at site 1 after transfection of the base editor ABE8e.

[0246] Figure 8 shows the editing efficiency of 004V1-nCas9 from A·T to G·C at site 17, which includes A to C. A in Figure 8 is a comparison of the editing efficiency of 004V1-nCas9 and ABE8e at site 17. The editing positions are adenine deoxynucleotides +3, +4, +5, and +7 from the 5' end of the sgRNA. The error bars represent the mean ± SEM, and there are 3 biological replicates for each group of samples; B in Figure 8 is the sequencing result at site 17 after transfection of the base editor 004V1-nCas9; C in Figure 8 is the sequencing result at site 17 after transfection of the base editor ABE8e.

[0247] Figure 9 shows the editing efficiency of 004V1-nCas9 from A·T to G·C at site 18, which includes A to C. Figure 9-A shows a comparison of the editing efficiency of p004V1-nCas9 and ABE8e at site 18. The editing positions are adenine deoxynucleotides +3, +5, +7, and +9 from the 5' end of the sgRNA. The error bars represent the mean ± SEM, and there are three biological replicates for each group of samples. Figure 9-B shows the sequencing results at site 18 after transfection of the base editor 004V1-nCas9; Figure 9-C shows the sequencing results at site 18 after transfection of the base editor ABE8e.

[0248] Figure 10 shows the editing efficiency of 004V1-nCas9 from A·T to G·C at the PCSK9 site, which includes A to C. Figure 10-A shows a comparison of the editing efficiency of 004V1-nCas9 and ABE8e at the PCSK9 site. The editing position is the adenine deoxynucleotide +6 from the 5' end of the sgRNA. The error bars represent the mean ± SEM. There are 3 biological replicates for each group of samples. Figure 10-B shows the sequencing results of the PCSK9 site after transfection of the base editor 004V1-nCas9; Figure 10-C shows the sequencing results of the PCSK9 site after transfection of the base editor ABE8e.

[0249] Figure 11 shows the editing efficiency of various mutants of adenosine deaminase 004V1 - nCas9 and ABE8e at different sites.

[0250] Figure 12 shows the editing efficiency of base editors composed of other mutants of adenosine deaminase 004V1 at different sites.

[0251] Figure 13 shows the base editing efficiency of some chimeric base editors and base editors with deaminases linked to the N-terminus or C-terminus of nCas9 at site 1 (site 1).

[0252] Figure 14 shows the base editing efficiency of some chimeric base editors and base editors with deaminases linked to the N-terminus or C-terminus of nCas9 at the PCSK9 site.

[0253] Figure 15 shows the base editing efficiency of some chimeric base editors and base editors with deaminases linked to the N-terminus or C-terminus of nCas9 at the FANCF site. DETAILED DESCRIPTION

[0254] Unless otherwise specified, the experiments and methods described in the embodiments are carried out substantially according to conventional methods well known in the art and described in various references. For example, conventional techniques such as immunology, biochemistry, chemistry, molecular biology, microbiology, cell biology, genomics and recombinant DNA used in the present invention can be found in Sambrook, Fritsch and Maniatis, MOLECULAR CLONING: A LABORATORY MANUAL, 2nd edition (1989); CURRENT PROTOCOLS IN MOLECULAR BIOLOGY (edited by FM Ausubel et al., (1987)); METHODS IN ENZYMOLOGY series (Academic Publishing Company): PCR 2: A PRACTICAL METHOD. APPROACH) (MJ MacPherson, BD Hames and GR Taylor, eds. (1995)), ANTIBODIES, A LABORATORY MANUAL (Harlow and Lane, eds. (1988)), and ANIMAL CELL CULTURE (RI Freshney, ed. (1987)).

[0255] Where specific conditions are not specified in the examples, the experiments were carried out under conventional conditions or the conditions recommended by the manufacturer. Reagents or instruments used, for which the manufacturer is not specified, are commercially available conventional products. Those skilled in the art will appreciate that the examples describe the present invention by way of example and are not intended to limit the scope of the invention. All publications and other references mentioned herein are incorporated herein by reference in their entirety.

[0256] Example 1 Obtaining base editors composed of adenosine deaminase 005V1 and its mutants

[0257] The applicant used bioinformatics functions to predict key amino acid sites that may affect its biological function and mutated the amino acid sites to obtain multiple adenosine deaminase mutants whose editing efficiency was significantly improved compared to the base editor composed of adenosine deaminase 005V1. The specific site amino acid mutation patterns of 005V1 deaminase are shown in Tables 1a and 1b, and the mutation patterns of each mutant are shown in Table 2.

[0258] Table 1a Specific amino acid mutation patterns of 005V1 deaminase

[0259] Table 1b Specific amino acid mutation patterns of 005V1 deaminase

[0260] Table 2 Mutation forms of various mutants of adenosine deaminase 005V1

[0261] Base editors with different deaminase variants were generated through PCR-based site-directed mutagenesis. The specific method is to amplify the DNA sequence encoding the 005V1-nCas9 base editor, centered around the 4-6 amino acids near the mutation site. Primers are then added to introduce the desired mutation sequence. The amplified fragments are then subjected to homologous recombination or enzyme ligation to generate different mutant base editors. The PCR primers used for these mutant base editors are shown in Tables 3-1, 3-2, and 3-3.

[0262] Table 3-1 PCR primers used for each mutant base editor

[0263] Table 3-2 PCR primers used for each mutant base editor

[0264] Table 3-3 PCR primers used for each mutant base editor

[0265] The applicant obtained the corresponding mutant base editor by site-directed mutagenesis of deaminase 005V1-nCas9 using PCR. The specific method is as follows:

[0266] As mentioned above, the applicant designed two mutation primers near the mutation site and inserted the sequence to be mutated into the mutation primers. The mutation primers used are shown in Tables 2 and 3. The full-length DNA sequence of the plasmid was amplified using 2×Phanta Flash Master Mix enzyme (Vazyme, P520) (according to the instructions). After amplification, the residual original template was digested with DpnI enzyme (NEB, R1076L). The target fragments were end-digested and ligated with T4 DNA ligase (NEB, R3733L) and T4 DNA ligase (NEB, M0202L). After transformation, the fragments were sent to Boshang Biotechnology Co., Ltd. for sequencing. The sequencing results showed that different mutants of 005V1-nCas9 with correct sequences had been obtained.

[0267] Example 2 Verification of editing activity of base editors constructed using 005V1-nCas9 and various deaminase mutants

[0268] (1) The construction process of sgRNA expression vector (sgRNA plasmid) is as follows:

[0269] PCSK9-sgRNA was designed for PCSK9 target sites according to the target sites of site 1 (site 1), site 8 (site 8), site 16 (site 16), and site 18 (site 18) (see Gaudelli NM, Komor AC, Rees HA, Packer MS, Badran AH, Bryson DI, Liu DR. Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage. Nature. 2017 Nov 23; 551(7681): 464-471. doi: 10.1038 / nature24644. Epub 2017 Oct 25. Erratum in: Nature. 2018 May 2;:PMID:29160308;PMCID:PMC5726555.) site1-sgRNA, site8-sgRNA, site16-sgRNA, and site18-sgRNA were designed. The specific sgRNAs are shown in Table 4.

[0270] Table 4

[0271] sgRNAs were designed based on the target sequence and oligonucleotides were synthesized. The sgRNA sequences used are shown in SEQ ID NOs: 141 to 145. A CACC sequence was added to the 5' end of the upstream sequence of each sgRNA, and an AAAC sequence was added to the 5' end of the downstream sequence. Therefore, the upstream sequence of each synthesized sgRNA was in the form of: 5'-CACCXXXXXXXXXXXXXXXXXXXXX(20nt)-3', and the downstream sequence was in the form of: 5'-AAACXXXXXXXXXXXXXXXXXXXXX(20nt)-3'. After synthesis, the upstream and downstream sequences were annealed using a preset program (95°C, 5 min; 95°C-85°C at -2°C / s; 85°C-25°C at -0.1°C / s; maintained at 4°C). The annealed product was ligated into the PHK09 vector (plasmid map shown in Figure 6A, in-house, which already contains the sgRNA backbone sequence) linearized with BsmBI (NEB: R0739L). The sequence of the PHK09 vector is shown below:

[0272] Among them, the system used in the construction of sgRNA plasmid is as follows:

[0273] The linearization system of PHK09 vector is as follows: 3 μg of PHK09 vector; 6 μL of buffer (NEB: R0539L); 2 μL of BsmBI; ddH2O is added to 60 μL, and enzyme digestion is carried out at 37°C overnight.

[0274] The sgRNA annealing product and linearized vector ligation system is as follows: T4 ligase buffer (NEB: M0202L) 1 μL, linearized vector 20 ng, annealed oligo fragment (10 μM) 5 μL, T4 ligase (NEB: M0202L) 0.5 μL, ddH2O is added to 10 μL, and ligation is carried out at 16°C overnight.

[0275] The ligated vector was transformed into Escherichia coli DH5α competent cells (Weidi Biotechnology, DL1001). The specific process is as follows: Remove the DH5α competent cells from -80°C and quickly place them on ice. After 5 minutes, allow the bacterial mass to thaw. Add the ligation product and gently mix by fingering the bottom of the centrifuge tube. Let it rest on ice for 25 minutes. Heat shock the tube in a 42°C water bath for 45 seconds, quickly return it to ice, and let it rest for 2 minutes. Add 700 μl of sterile LB medium without antibiotics to the centrifuge tube, mix thoroughly, and then recover at 37°C, 200 rpm, for 60 minutes. Harvest the cells by centrifugation at 5000 rpm for one minute. Retain approximately 100 μl of the supernatant, gently pipette to resuspend the bacterial mass, and spread it onto LB medium supplemented with Amp antibiotics. Place the plate upside down in a 37°C incubator overnight. Single colonies were picked, and after sequencing confirmation, positive clones were shaken out and the plasmid (TIANGEN, DP120-01) was extracted and the concentration was determined. The cells were then stored in a -20°C refrigerator until further use.

[0276] (2) Cell culture and transfection

[0277] HEK293T cells (purchased from ATCC) were seeded in DMEM (Gibco, 11965092) supplemented with 10% FBS (v / v) and 1% Penicillin Streptomycin (Gibco, 15140122) (v / v) and cultured in a 37°C cell culture incubator with 5% CO2. Cells for transfection were seeded in 24-well cell culture plates the day before and observed the next day. Transfection was performed when the cells reached a cell density of approximately 80%. The plasmid dosage for each well of the 24-well plate was 0.4 μg of the 005V1-nCas9 plasmid and each 005V1 mutant-nCas9 plasmid, and 0.4 μg of the sgRNA plasmid. The plasmid mixture was diluted with 25 μl of reduced serum medium (Source Biotechnology, L530KJ), and 2 μl of p3000 reagent was added. Mixing by pipetting was performed as Reagent A, and the cells were allowed to stand for 5 minutes. At the same time, 2 μl of Lipofectamine 3000 transfection reagent (Thermo, 11668019) was diluted with 25 μl of reduced serum medium and mixed as reagent B, and allowed to stand for 5 minutes. Mix the above reagents A and B and pipette evenly, and let it stand for 20 minutes. After the standing period, the mixed reagent was added dropwise to the 24-well plate cells to be transfected and returned to the 37°C incubator for culture. After 6 hours of transfection, the culture medium was replaced with DMEM medium containing 10% FBS. After 48 hours of transfection, the cells were collected for testing of editing efficiency.

[0278] (3) The collected cells were subjected to genome extraction (TIANGEN, DP304-03), and primers were designed according to experimental requirements. The identification primer sequences used are shown in Table 5.

[0279] Table 5 Design of primers for identification of various targets

[0280] Using the genome as a template, PCR amplification of sequences near the target site was performed, and the amplified PCR products were used for high-throughput deep sequencing (Genwizhi Biotechnology Co., Ltd.) or Sanger sequencing (Boshang Biotechnology (Shanghai) Co., Ltd.) to identify the editing efficiency. The system used for target site sequence amplification is as follows: 2× Taq Master Mix (Vazyme, P112-03) 25μL; Primer-F (10pmol / μL) 1μL; Primer-R (10pmol / μL) 1μL; Template 1μL; ddH2O to 50μL. Gene Editing Effect Detection:

[0281] For the method of calculating gene editing efficiency, see Kluesner MG, Nedveck DA, Lahr WS, Garbe JR, Abrahante JE, Webber BR, Moriarity BS. EditR: A Method to Quantify Base Editing from Sanger Sequencing. CRISPR J. 2018 Jun; 1(3): 239-250. doi: 10.1089 / crispr.2018.0014. PMID: 31021262; PMCID: PMC6694769.

[0282] In this embodiment, the structure of the base editor comprising adenosine deaminase and nCas9 provided by the present invention is as follows:

[0283] NH2-[NLS]-[Adenosine Deaminase]-Linker-[nCas9]-[NLS]-COOH. This is for illustrative purposes only and does not limit the structure of the base editor. Examples of this structure can be found in SEQ ID NO:3 and SEQ ID NO:190.

[0284] In this example, the editing efficiency of each base editor for the PCSK9 target (the efficiency of mutating adenine A to guanine G) was statistically analyzed. The editing efficiency of the base editors was measured and compared. The editing efficiency of the base editors composed of 005V1-nCas9 and various deaminase mutants is shown in Tables 6-9:

[0285] Table 6

[0286] Table 7

[0287] Table 8

[0288] Table 9

[0289] The editing efficiency and comparison of 005V1-nCas9 and the editors composed of various mutants are shown in Figures 2-5.

[0290] Figure 2 shows the editing efficiency of 005V1-nCas9 and various mutants of 005V1-nCas9 at the PCSK9 site from A·T to G·C. The editing position is the adenine deoxynucleotide +6 from the 5' end of the sgRNA. The error bars represent the mean ± SEM. Each group of samples had 3 to 5 biological replicates.

[0291] As shown in Figure 3, 005V1-10-3-nCas9, 005V1-11-2-nCas9, 005V1-10-1-nCas9, 005V1-10-4-nCas9, 005V1-11-3-nCas9, 005V1-15-1-nCas9, 005V1-11-5-nCas9, 005V1-11-4-nCas9, 00 The editing efficiency of 5V1-15-2-nCas9, 005V1-3-3-nCas9, 005V1-5-4-nCas9, 005V1-15-5-nCas9, 005V1-5-8-nCas9, 005V1-10-5-nCas9, 005V1-5-2-nCas9, 005V1-3-6-nCas9, and 005V1-2-7-nCas9 at the PCSK9 site was significantly improved, with an average editing efficiency of more than 20%, which was 1.07 to 2.41 times higher than that of the original 005V1-nCas9.

[0292] As shown in Figure 4, among the mutants with significantly improved editing efficiency at the PCSK9 locus, 005V1-10-3-nCas9 achieved an editing efficiency of 46.67%. 005V1-11-2-nCas9 and 005V1-10-1-nCas9 also achieved editing efficiencies of 35.67% and 35.33%, respectively. Most of the other base editors constructed from the mutants shown in the figure also exhibited higher editing efficiencies than 005V1-nCas9.

[0293] As shown in Figure 5, the editing windows of 005V1-5-4-nCas9, 005V1-3-3-nCas9, 005V1-5-2-nCas9, 005V1-2-7-nCas9, 005V1-3-6-nCas9, 005V1-2-8-nCas9, 005V1-5-3-nCas9, and 005V1-3-4-nCas9 at site 1 (+5 position, +7 position), the editing windows at site 8 (+2 position, +3 position, +4 position, +6 position), and the editing windows at site 16 (+3 position, +4 position, +6 position) are significantly narrowed. While the editing windows of the above-mentioned base editors at site 1 are narrowed, they still maintain extremely high editing activity for the adenine deoxynucleotide at the +5 position from the 5' end of the sgRNA in the window, which can achieve efficient and precise editing and has great potential application value.

[0294] Example 3

[0295] This example uses adenosine deaminase 004V1 and fuses it with nCas9 to form a new adenine base editor 004V1-nCas9 with a narrower editing window.

[0296] In this embodiment, the construction strategy of the adenine base editor 004V1-nCas9 is: replace the adenosine deaminase in ABE8e with 004V1, thereby obtaining a new adenine base editor 004V1-nCas9.

[0297] In the following examples, the structure of the base editor comprising adenosine deaminase and nCas9 provided by the present invention is as follows:

[0298] NH2-[NLS]-[adenosine deaminase]-linker-[napDNAbp]-[NLS]-COOH. However, this is only used as an example and is not intended to limit the structure of the base editor.

[0299] In the following examples, the sgRNA used is shown in Table 10, and the identification primer sequences used are shown in Table 11.

[0300] Table 10

[0301] Table 11

[0302] The specific construction of sgRNA and base editor is as follows.

[0303] 1. The construction method of sgRNA expression vector (sgRNA plasmid) is the same as that in Example 2.

[0304] 2. Construction of the adenine base editor 004V1-nCas9 expression vector (004V1-nCas9 plasmid)

[0305] In this example, an adenine base editor expression vector 004V1-nCas9 was prepared. The nucleotide sequence of adenosine deaminase 004V1 is shown in SEQ ID NO: 156.

[0306] Nucleotide sequence of 004V1:

[0307] The nucleotide sequence of the deaminase 004V1 gene was codon-optimized based on human codon usage preferences. A 540-bp synthetic copy of the deaminase 004V1 gene was commissioned to Sangon Biotech (Shanghai) Co., Ltd., and the synthesized gene replaced nucleotides 63-560 of the ABE8e sequence. A plasmid map of 004V1-nCas9 is shown in Figure 6B. (Correspondingly, the amino acid sequence of 004V1-nCas9 is shown in SEQ ID NO: 190.)

[0308] The nucleotide sequence of 004V1-nCas9 is shown below:

[0309] 3. Cell culture and transfection

[0310] HEK293T cells (purchased from ATCC) were seeded in DMEM (Gibco, 11965092) supplemented with 10% FBS (v / v) and 1% Penicillin Streptomycin (Gibco, 15140122) (v / v) and cultured in a 37°C cell culture incubator with 5% CO2. Cells for transfection were seeded in 24-well cell culture plates the day before and observed the next day. Transfection was performed when the cells reached a cell density of approximately 80%. The plasmid dosage per well of the 24-well plate was 0.4 μg of p004V1-nCas9 plasmid and 0.4 μg of sgRNA plasmid, respectively. The plasmid mixture was diluted in 25 μl of reduced serum medium (Source Biotechnology, L530KJ). 2 μl of p3000 reagent was added and mixed thoroughly by pipetting, which served as Reagent A. The cells were then allowed to stand for 5 minutes. At the same time, 2 μl of Lipofectamine 3000 transfection reagent (Thermo, 11668019) was diluted with 25 μl of reduced serum medium and mixed as reagent B. The mixture was allowed to stand for 5 minutes. The above reagents A and B were mixed and pipetted evenly, and allowed to stand for 20 minutes. After the standing period, the mixed reagents were added dropwise to the 24-well plate cells to be transfected and returned to the 37°C incubator for culture. After 6 hours of transfection, the culture medium was replaced with DMEM medium containing 10% FBS. After 48 hours of transfection, the cells were collected for testing of editing efficiency.

[0311] 4. Detection of the editing efficiency of the adenine base editor 004V1-nCas9 in this example at endogenous gene sites

[0312] The cells described in "3. Cell culture and transfection" were subjected to genomic extraction (TIANGEN, DP304-03). Primers were designed according to experimental requirements, and the identification primer sequences used are shown in SEQ ID NO: 148-149, 166-167, 154-155 in Table 11. Using the genome as a template, the sequence near the target site was PCR amplified, and the amplified PCR product was used for high-throughput deep sequencing (Jinweizhi Biotechnology Co., Ltd.) or Sanger sequencing (Boshang Biotechnology (Shanghai) Co., Ltd.) to identify the editing efficiency. The system for target site sequence amplification is as follows: 2×Taq Master Mix (Vazyme, P112-03) 25 μL; Primer-F (10 pmol / μL) 1 μL; Primer-R (10 pmol / μL) 1 μL; Template 1 μL; ddH2O is filled to 50 μL.

[0313] The gene editing effect test process is as follows:

[0314] The 004V1-nCas9 plasmid was co-transfected with sgRNA plasmids at different sites into HEK293T cells (purchased from ATCC). Compared with the ABE8e plasmid (addgene, Plasmid #138489), the editing efficiency of 004V1-nCas9 was similar to that of ABE8e at sites 1 and 17 ( Figures 7 and 8 ), while the editing efficiency of 004V1-nCas9 at site 18 was significantly better than that of ABE8e ( Figure 9 ).

[0315] As for the editing window, the editing windows of 004V1-nCas9 at sites 1, 17, and 18 are all smaller than those of ABE8e (see Figures 7 to 9).

[0316] For the calculation method of gene editing efficiency, see Kluesner MG, Nedveck DA, Lahr WS, Garbe JR, Abrahante JE, Webber BR, Moriarity BS. EditR: A Method to Quantify Base Editing from Sanger Sequencing. CRISPR J. 2018 Jun; 1(3): 239-250. doi: 10.1089 / crispr.2018.0014. PMID: 31021262; PMCID: PMC6694769. The relevant results of this example are shown in Figures 7-9.

[0317] Example 4

[0318] In this example, the adenine base editor 004V1-nCas9 obtained in Example 3 was applied to disease treatment.

[0319] Proprotein convertase subtilisin / kexin type 9 (PCSK9) is the ninth member of the kexin-like proprotein convertase subtilisin family and consists of 692 amino acid residues. As a negative regulator of the low-density lipoprotein receptor (LDLR), excessive PCSK9 binds to the LDLR on the surface of hepatocytes, accelerating its degradation. This leads to decreased hepatocyte uptake of low-density lipoprotein cholesterol (LDL-C), which in turn increases circulating LDL-C levels, ultimately raising blood cholesterol levels.

[0320] 1. Construction of sgRNA expression vector (sgRNA plasmid)

[0321] The construction method of the sgRNA plasmid targeting PCSK9 in this example is as described in Example 1. The sgRNA sequence used is shown in SEQ ID NO: 141.

[0322] PCSK9-sgRNA: Cccgcaccttggcgcagcgg (SEQ ID NO: 141).

[0323] 2. Cell culture and transfection

[0324] The culture and transfection methods of HEK293T cells in this example are the same as those in Example 3.

[0325] 3. Detection of editing efficiency of optimized base editing tools at the PCSK9 site

[0326] The editing efficiency detection method in this example is the same as that described in Example 1, and the identification primer sequences used are shown in SEQ ID NOs: 146-147.

[0327] PCSK9-forward primer: Gctagccttgcgttccg (SEQ ID NO: 146);

[0328] PCSK9-Reverse Primer: Gtccccaagatcgtgccaa (SEQ ID NO: 147).

[0329] In this example, the adenine base editor expression vector p004V1-nCas9 and a PCSK9-targeting sgRNA plasmid were co-transfected into HEK293T cells. As shown in Figure 10, the editing efficiency of 004V1-nCas9 was superior to that of the ABE8e adenine base editor, indicating that the base editor 004V1-nCas9 can be used to target hypercholesterolemia caused by overexpression of PCSK9.

[0330] Example 5

[0331] In this example, mutants of adenosine deaminase 004V1, adenosine deaminase 004V2, adenosine deaminase 004V3, adenosine deaminase 004V4, adenosine deaminase 004V7, adenosine deaminase 004V8, adenosine deaminase 004V10, adenosine deaminase 004V12, and adenosine deaminase 004V13, were used to construct an adenine base editor expression vector and an sgRNA expression vector using the same method as in Example 3 or Example 4. Cell culture and transfection were performed to detect the editing efficiency.

[0332] The amino acid sequence information of the base editor composed of the above mutants is as follows:

[0333] 004V2-nCas9 (SEQ ID NO:191), 004V3-nCas9 (SEQ ID NO:192), 004V4-nCas9 (SEQ ID NO:193), 004V7-nCas9 (SEQ ID NO:194), 004V8-nCas9 (SEQ ID NO:195), 004V10-nCas9 (SEQ ID NO:196), 004V12-nCas9 (SEQ ID NO:197), 004V13-nCas9 (SEQ ID NO:198).

[0334] The base editing efficiency results are shown in Figure 11. As shown in Figure 11, compared to ABE8e, the editing windows of 004V2-nCas9, 004V3-nCas9, 004V4-nCas9, 004V7-nCas9, 004V8-nCas9, 004V10-nCas9, 004V12-nCas9, and 004V13-nCas9 at site 1 are significantly narrower (+5, +7). Among them, 004V12-nCas9 has the narrowest editing window, with editing activity only at position +5, and a base editing efficiency of 46%, achieving efficient and precise editing. At site 18, the editing efficiency of different 004V1-nCas9 mutants is significantly better than that of ABE8e. At the PCSK9 site, the editing efficiency of 004V1-nCas9 and 004V3-nCas9 is also better than that of ABE8e.

[0335] The nucleotide sequences of the base editors composed of each adenosine deaminase are as follows

[0336] Nucleotide sequence of 004V2-nCas9:

[0337] Nucleotide sequence of 004V3-nCas9:

[0338] Nucleotide sequence of 004V4-nCas9:

[0339] Nucleotide sequence of 004V7-nCas9:

[0340] Nucleotide sequence of 004V8-nCas9:

[0341] Nucleotide sequence of 004V10-nCas9:

[0342] Nucleotide sequence of 004V12-nCas9:

[0343] Nucleotide sequence of 004V13-nCas9:

[0344] Example 6

[0345] The other amino acid positions of adenosine deaminase 004V1 were also mutated to obtain adenosine deaminase 004V14, adenosine deaminase 004V15, adenosine deaminase 004V16, adenosine deaminase 004V17, adenosine deaminase 004V18, adenosine deaminase 004V19, adenosine deaminase 004V20, adenosine deaminase 004V21, adenosine deaminase 004V22, adenosine deaminase 004V23, adenosine deaminase 004V24, adenosine deaminase 004V25, adenosine deaminase 004V26, adenosine deaminase 004V27, adenosine deaminase 004V28, Adenosine deaminase 004V28, adenosine deaminase 004V29, adenosine deaminase 004V30, adenosine deaminase 004V31, adenosine deaminase 004V32, adenosine deaminase 004V33, adenosine deaminase 004V34, adenosine deaminase 004V35, adenosine deaminase 004V36, adenosine deaminase 004V37, adenosine deaminase 004V38, adenosine deaminase 004V39, adenosine deaminase 004V40 and adenosine deaminase 004V41, the amino acid mutation pattern is shown in Table 12, and the amino acid mutation pattern involved in each deaminase mutant is shown in Table 13.

[0346] Table 12 Amino acid mutation patterns of various deaminase mutants

[0347] Table 13 Mutation patterns of various deaminase mutants

[0348] The same method as in Example 2-4 was used to construct an adenine base editor expression vector composed of adenosine deaminase 004V14-004V41 and a PCSK9-sgRNA expression vector. Cell culture and transfection were performed in the same manner as in the above example. The gene editing effect test process was as follows:

[0349] For the method of calculating gene editing efficiency, see Kluesner MG, Nedveck DA, Lahr WS, Garbe JR, Abrahante JE, Webber BR, Moriarity BS. EditR: A Method to Quantify Base Editing from Sanger Sequencing. CRISPR J. 2018 Jun; 1(3): 239-250. doi: 10.1089 / crispr.2018.0014. PMID: 31021262; PMCID: PMC6694769.

[0350] The editing efficiency of the base editors composed of the above-mentioned adenosine deaminase 004V1 and nCas9 is compared with the editing efficiency of deaminase 004V1-nCas9 as follows:

[0351] The relevant results of this example are shown in Figure 12. Compared to 004V1-Cas9, the base editors composed of deaminases 004V14-004V32 and nCas9 all showed higher editing efficiency at the PCSK9 locus than 004V1-nCas9. The editing efficiency of base editors composed of adenosine deaminases 004V14-004V29 and nCas9 was significantly improved compared to 004V1-nCas9. The editing efficiency of 004V17-nCas9 to 004V29-nCas9 increased by more than 20% compared to 004V1-nCas9. In particular, the editing efficiency of 004V14-nCas9, 004V15-nCas9, and 004V16-nCas9 was more than twice that of 004V1-nCas9.

[0352] Example 7

[0353] To further improve the editing efficiency of base editor fusion proteins, the applicant explored the structure of base editor fusion proteins. A suitable insertion site for adenosine deaminase was found within the nCas9 protein. The adenosine deaminases used included adenosine deaminase 005V1, 005V1-10-1, and 005V1-10-3. The sequences of the three adenosine deaminases are shown in Example 1. The experimental steps are as follows:

[0354] 1. Construction of nCas9 Plasmid

[0355] (1) Design of primers (synthesized by Shanghai Boshang Biotechnology Co., Ltd.):

[0356] Table 14

[0357] ABE8e (Addgene, #138489) was amplified by PCR using a high-fidelity enzyme kit (Vazyme, P501-d2) from Novagen. The amplification system is shown in Table 15:

[0358] Table 15

[0359] The PCR amplification program is shown in the table below:

[0360] Table 16

[0361] The amplified PCR product was recovered according to the kit instructions (Tian Gen, Universal DNA Purification and Recovery Kit, DP214).

[0362] The purified PCR product was transformed into E. coli DH5α competent cells (Weidi Biotechnology, DL1001). The specific process is as follows: Remove the DH5α competent cells from -80°C and quickly place them on ice. After 5 minutes, allow the bacterial mass to thaw. Add the ligation product and gently mix by flicking the bottom of the centrifuge tube. Let it rest on ice for 25 minutes. Heat shock the tube in a 42°C water bath for 45 seconds, quickly return it to ice, and let it rest for 2 minutes. Add 700 μl of sterile LB medium without antibiotics to the centrifuge tube, mix thoroughly, and then recover at 37°C, 200 rpm for 60 minutes. Centrifuge at 5000 rpm for one minute to harvest the cells. Collect approximately 100 μl of the supernatant, gently pipette to resuspend the bacterial mass, and spread it onto LB medium containing the Amp antibiotic. Incubate the plate upside down in a 37°C incubator overnight. Single colonies were picked, and after sequencing confirmation, the positive clones were shaken and the nCas9 plasmid was extracted using an endotoxin-free plasmid extraction kit (TIANGEN: DP120-01) and the concentration was measured. The plasmids were then stored in a -20°C refrigerator for later use.

[0363] (2) Obtaining DNA sequences encoding deaminases 005V1, 005V1-10-1, and 005V1-10-3

[0364] PCR amplification was performed on 005V1-nCas9, 005V1-10-1-nCas9, and 005V1-10-3-nCas9 plasmids using primers. The amplification system and PCR program were the same as in Tables 15 and 16. The amplified PCR products were recovered according to the kit instructions (Tian Gen, Universal DNA Purification and Recovery Kit, DP214).

[0365] The PCR primers used are shown in the following table:

[0366] Table 17

[0367] (3) Design of different chimeric base editors and primer sequences corresponding to nCas9 plasmids

[0368] The insertion positions of deaminases 005V1, 005V1-10-1, and 005V1-10-3 in nCas9 were studied, and a variety of chimeric base editors were designed. The primer sequences corresponding to nCas9 were designed according to the different insertion positions of the above deaminases, as shown in Table 18.

[0369] Table 18

[0370] The primer sequences corresponding to the nCas9 plasmids for the different chimeric base editors described in Table 18 are designed as follows:

[0371] Table 19

[0372] The nCas9 plasmids obtained in step (1) were amplified using the primer sequences in Table 19. The amplification system and PCR procedures were the same as those in Tables 15 and 16. The amplified PCR products were recovered according to the kit instructions (Tian Gen, Universal DNA Purification and Recovery Kit, DP214). The primers used for amplification of nCas9 plasmids corresponding to different insertion positions are shown in Table 19. For example, the amino acid sequence of 005V1-1249-ABE is shown below:

[0373] Among them, italics represent NLS, bold represents nCas9 fragment, underline represents linker, double underline represents deaminase, and the asterisk at the C-terminus represents the stop codon position; the deaminase sequence is deaminase 005V1, and the deaminase 005V1 is embedded in the nCas9 position between 1249-1250.

[0374] (4) The PCR products of adenosine deaminase 005V1, 10-1, and 10-3 obtained in step (2) were homologously recombined with the linearized PCR products at different insertion positions in step (3) using the Gibson Assembly Master Mix Recombination Kit (NEB, E2611S) to obtain different chimeric recombinant plasmids. The reaction system is shown in the following table:

[0375] Table 19

[0376] The homologous recombination product was transformed into Escherichia coli DH5α competent cells (Weidi Biotechnology, DL1001). The specific process is as follows: Remove the DH5α competent cells from -80°C and quickly place them on ice. After 5 minutes, allow the bacterial mass to thaw. Add the ligation product and gently mix by flicking the bottom of the centrifuge tube. Let it rest on ice for 25 minutes. Heat shock the tube in a 42°C water bath for 45 seconds, quickly return it to ice, and let it rest for 2 minutes. Add 700 μl of sterile LB medium without antibiotics to the centrifuge tube, mix thoroughly, and then recover at 37°C, 200 rpm for 60 minutes. Centrifuge at 5000 rpm for one minute to harvest the cells. Collect approximately 100 μl of the supernatant, gently pipette to resuspend the bacterial mass, and spread it onto LB medium containing the Amp antibiotic. Incubate the plate upside down in a 37°C incubator overnight. Single colonies were picked, and after sequencing confirmation, the positive clones were shaken and the chimeric recombinant plasmid was extracted using an endotoxin-free plasmid extraction kit (TIANGEN: DP120-01) and the concentration was measured. The plasmid was then stored in a -20°C refrigerator for later use.

[0377] (5) Cell culture and transfection

[0378] HEK293T cells (purchased from ATCC) were inoculated in DMEM medium (Gibco, 11965092) supplemented with 10% FBS (v / v) and 1% Penicillin Streptomycin (v / v) (Gibco, 15140122) and cultured in a 37°C cell culture incubator with 5% CO2. The cells used for transfection were inoculated in 24-well cell culture plates the day before and cultured. The cells were observed the next day and transfected when the cells grew to a cell density of about 80%. The amount of plasmids transfected per well of the 24-well plate was 0.4 μg of the chimeric recombinant plasmid and 0.4 μg of the sgRNA plasmid. The sgRNAs used are shown in the following table:

[0379] Table 20

[0380] The PCSK9-sgRNA and site1-sgRNA sequences used in this example are the same as the corresponding sequences in other examples, and the FANCF-sgRNA is an sgRNA targeting the FANCF gene.

[0381] After mixing the chimeric recombinant plasmid and sgRNA plasmid, dilute with 25μl of reduced serum medium (Source Bio, L530KJ) and add 2μl of p3000 reagent. Mix by pipetting as reagent A and let it stand for 5 minutes. At the same time, dilute 2μl of Lipofectamine3000 transfection reagent (Thermo, 11668019) with 25μl of reduced serum medium and mix well as reagent B. Let it stand for 5 minutes. Mix the above reagents A and B and pipette evenly, let it stand for 20 minutes. After the standing period, add the mixed reagent dropwise to the 24-well plate cells to be transfected and return them to the 37°C incubator for culture. After 6 hours of transfection, the culture medium was replaced with DMEM medium containing 10% FBS. 48 hours after transfection, the cells were collected for editing efficiency detection.

[0382] (6) Editing efficiency detection

[0383] Genomic DNA extraction was performed on HEK293T cells using a genomic DNA extraction kit (TIANGEN, DP304-03). Primers were designed according to experimental requirements. The identification primer sequences used are shown in Table 21.

[0384] Table 21

[0385] Using the genome as a template, the sequence near the sgRNA target site was amplified by PCR using identification primers, and the amplified PCR products were sequenced by Sanger sequencing (Boshang Biotechnology (Shanghai) Co., Ltd.) to identify the editing efficiency.

[0386] The system used for target site sequence amplification is as follows:

[0387] 2×Taq Master Mix (Vazyme, P112-03) 25 μL; Primer-F (10 pmol / μL) 1 μL; Primer-R (10 pmol / μL) 1 μL; Template 1 μL; ddH2O to make up to 50 μL.

[0388] For the method of calculating gene editing efficiency, see Kluesner MG, Nedveck DA, Lahr WS, Garbe JR, Abrahante JE, Webber BR, Moriarity BS. EditR: A Method to Quantify Base Editing from Sanger Sequencing. CRISPR J. 2018 Jun; 1(3): 239-250. doi: 10.1089 / crispr.2018.0014. PMID: 31021262; PMCID: PMC6694769.

[0389] The results of this example are shown in Figures 13-15. The base editing efficiencies of various chimeric base editors and base editors with deaminases linked to the N-terminus or C-terminus of nCas9 at site 1 are shown in Figure 13. As can be seen, at site 1, base editors 005V1-C-ABE, 005V1-10-1-C-ABE, and 005V1-10-3-C-ABE all showed no editing activity. For other base editors, 005V1-1047-1064-ABE, 005V1-1048-1063-ABE, and 005V1-1249-ABE showed significantly higher editing efficiencies at position A5 of site 1 than 005V1-N-ABE, with 005V1-1249-ABE showing nearly double the editing efficiency of 005V1-N-ABE. 005V1-776-ABE, 005V1-793-ABE, 005V1-905-ABE, and 005V1-919-ABE showed higher base editing efficiency at specific positions in site 1 than 005V1-N-ABE. This can be exploited to achieve editing at specific gene locations for disease treatment. 005V1-10-1-1249-ABE showed higher editing efficiency at all positions in site 1 than 005V1-10-1-N-ABE. 005V1-10-3-1249-ABE showed higher editing efficiency at all positions in site 1 than 005V1-10-3-N-ABE. This indicates that for 005V1 and its mutants 005V1-10-1 and 005V1-10-3, better editing efficiency is achieved when nCas9 is inserted between positions 1249 and 1250.

[0390] At the PCSK9 site, the base editing efficiencies of various chimeric base editors and base editors with deaminases linked to the N-terminus or C-terminus of nCas9 are shown in Figure 14. As can be seen, at the PCSK9 site, the editing efficiency of 005V1-1249-ABE is higher than that of 005V1-N-ABE, the editing efficiency of 005V1-10-1-1249-ABE is higher than that of 005V1-10-1-N-ABE, and the editing efficiency of 005V1-10-3-1249-ABE is higher than that of 005V1-10-3-N-ABE.

[0391] Figure 15 shows the base editing efficiencies of various chimeric base editors and base editors with deaminases linked to the N- or C-terminus of nCas9 at the FANCF locus. As can be seen, at the FANCF locus, 005V1-1249-ABE exhibited higher editing efficiency than 005V1-N-ABE at specific positions, and its editing properties at some positions differed from those of 005V1-N-ABE. 005V1-10-1-1249-ABE demonstrated editing efficiency at positions A10 and A12 of the same locus, while 005V1-10-1-N-ABE showed no editing activity at these positions. Its editing activity at other positions was comparable to that of 005V1-10-1-N-ABE. 005V1-10-3-1249-ABE exhibited similar properties to 005V1-10-1-1249-ABE at this site, showing editing efficiency at positions A10 and A12, while 005V1-10-3-N-ABE did not show editing activity at these positions, and the editing activity at other positions was not much different from that of 005V1-10-3-N-ABE.

Claims

1. An adenosine deaminase comprising one or more of the following sequences: (i) the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 170; (ii) an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 170, and which retains the deamination activity of the amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 170; (iii) an amino acid sequence in which one or more amino acid residues are added, substituted, deleted or inserted into the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 170, and which retains the deamination activity of the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 170; or (iv) an amino acid sequence encoded by a nucleotide sequence that hybridizes to a polynucleotide sequence encoding the amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 170 under stringent conditions, and the amino acid sequence retains the deamination activity of the amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 170, wherein the stringent conditions are moderate stringency conditions, medium-high stringency conditions, high stringency conditions or very high stringency conditions.

2. The adenosine deaminase according to claim 1, wherein The adenosine deaminase has changes in any of the following amino acid positions relative to the amino acid sequence shown in SEQ ID NO: 1: 33, 35, 36, 46, 47, 48, 49, 104, 105, 107, 148, 149, 150, 151, 152, 153, 154, 155.

3. The adenosine deaminase according to claim 1, wherein The substitution is a substitution occurring at one or more of the following positions in the amino acid sequence as shown in SEQ ID NO: 170: S15, D16, H17, E18, F19, N20, D21, E22, Y23, W24, M25, R26, H27, A28, L29, T30, K33, R34, A35, R36 , V41, V43, L47, L49, N51, N59, A61, I62, L64, A69, E72, G80, L81, V82, L83, Q84, N85, Y86, I89, D9 0. A91, T92, V95, F97, A106, R111, I112, S113, R114, L115, F117, V119, R120, N121, S122, K123, R 124, N132, V133, L134, N135, P137, G138, M139, N140, H141, R142, E144, D160, V168, F169, N170.

4. The adenosine deaminase according to claim 2, wherein the deaminase comprises a change selected from the group consisting of the following amino acid positions relative to the amino acid sequence of SEQ ID NO: 1: V33I, D35G, D35R, D36G, D36N, A46C, I47Y, I47R, I47V, T48G, T48R, L49T, L4 9K, L49H, V104A, V104M, S105C, S105G, S107R, S107K, S107A, Q148P, Q148C, Q148A, Q148G, Q149M, Q149G, Q149L, P150R, P150L, ​​P150C, R151K, E152R, E152T, E15 2G, E152W, V153P, V153F, V153I, V153T, F154H, F154K, F154L, N155T, N155R, N155H.

5. The adenosine deaminase according to claim 4, wherein The adenosine deaminase comprises an alteration selected from any one of the following groups relative to the amino acid sequence shown in SEQ ID NO: 1: (1)Q148G+Q149M+P150R; (2) S107A; (3) E152R+V153P+F154H+N155T; (4) S107K; (5) Q148P+Q149G+P150L; (6 )A46C+I47Y+T48G+L49H; (7)E152T+V153F+N155T; (8)S107R; (9)V104M; (10)E152G+V153I+F154K+N155R; ( 11)S105C; (12)Q148C+Q149L+P150R+R151K; (13)Q148A+Q149G+P150C; (14)E152W+V153T+F154L+N155H; (1 5)S105G; (16)I47R+T48G+L49T; (17)D35G+D36N; (18)V33I+D35R+D36G; (19)V104A; (20)I47V+T48R+L49K.

6. The adenosine deaminase according to claim 3, wherein the substitution occurs at one or more of the following positions of the amino acid sequence as shown in SEQ ID NO: 170: S15T, S15G, D16E, D16N, H17C, H17K, E18D, E18K, F19C, F19Y, F19S, N20Q, N20L, N20S, D21Q, E22D, Y23F, W24F, M25L, M25V, R26K, R26T, H27R, A28C, L29I, T30E, K33R, K33S, R34K, A35S, R36Q, L49F, N51G, L64M, L64Q, L64P, G80A, L81N, V8 2A, V82T, L83I, L83Q, Q84N, N85S, Y86W, I89E, I89L, D90G, A91C, A91T, T92D, A106C, I112L, S113K, R114K, V119L, S122N, S122P, R124H, R 124T, N132K, V133I, L134F, N135H, N135S, P137F, G138A, M139L, N140K, H141A, R142L, R142S, E144H, D160E, V168A, F169C, F169V, N170D; Preferably, the substitution is a combination of the following positions in the amino acid sequence as shown in SEQ ID NO: 170: (1)S15T+D16E+H17K+F19Y+N20Q; (2)E22D+Y23F+W24F+R26K+H27R+L29I; (3 )K33R+R34K+A35S; (4)G80A+L81N+V82A+L83I+Q84N+N85S+Y86W; (5)I89L+D9 0G+A91T+T92D; (6)I112L+S113K+R114K; (7)N132K+V133I+L134F+N135H; (8) P137F+G138A+M139L; (9)E18K+F19S+N20L; (10)M25L; (11)S15G+D16N+H17C; (12)L64Q+S122P+V168A; (13)R36Q+L64Q+S122P+F169V; (14)R36Q+V119L+V168A; (15)R36Q+V119L+N170D; (16)L64Q+V119L+ V168A; (17) F169C; (18) L64Q+V119L+V168A; (19) L64P+R124T+F169V; (20) I89E+A91C; (21) L64Q+V119L+F169V; (22) L64M; (23 )L64Q+S122P+N170D; (24)E18D+F19C+N20S; (25)L64P+V119L+N170D; (26)S122N+R124H+N135S+D160E; (27)R26T+H27R+A28C ; (28)V82T+L83Q; (29)M25V; (30)D21Q+T30E+K33S; (31)N140K+H141A+R142S; (32)L49F+N51G; (33)A106C; (34)R142L+E144H.

7. A base editor fusion protein comprising the adenosine deaminase according to any one of claims 1 to 6, and a nucleic acid programmable nucleotide binding domain.

8. The base editor fusion protein according to claim 7, wherein The nucleic acid programmable nucleotide binding domain is a Cas protein or an AGO protein.

9. The base editor fusion protein according to claim 7 or 8, wherein The base editor fusion protein further includes at least one nuclear localization signal sequence; Optionally, the base editor fusion protein further comprises a linker; Optionally, the linker comprises one or more of the sequences shown in SEQ ID NOs: 171-180; Optionally, the nuclear localization signal sequence comprises one or more of the sequences shown in SEQ ID NOs: 181-189.

10. The fusion protein according to claim 8, wherein the Cas protein comprises Cas9, Cas12 or Cas13 family.

11. The fusion protein according to claim 10, wherein the Cas protein comprises SpCas9, SaCas9, Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h, Cas12i, Cas12j or Cas13.

12. The fusion protein according to claim 10 or 11, wherein the Cas protein is an inactivated nuclease or a nicking nuclease.

13. The base editor fusion protein according to any one of claims 7 to 12, wherein The base editor fusion protein comprises one or more of the following sequences: (i) the amino acid sequence shown in SEQ ID NO: 190 or SEQ ID NO: 3; (ii) an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence set forth in SEQ ID NO: 190 or SEQ ID NO: 3, and which retains the polynucleotide binding and base editing activity of the amino acid sequence set forth in SEQ ID NO: 190 or SEQ ID NO: 3; (iii) an amino acid sequence in which one or more amino acid residues are added, substituted, deleted, or inserted into the amino acid sequence of SEQ ID NO: 190 or SEQ ID NO: 3, and which retains the polynucleotide binding and base editing activity of the amino acid sequence of SEQ ID NO: 190 or SEQ ID NO: 3; or (iv) an amino acid sequence encoded by a nucleotide sequence that hybridizes to a polynucleotide sequence encoding the amino acid sequence as shown in SEQ ID NO: 190 or SEQ ID NO: 3 under stringent conditions, and the amino acid sequence retains the binding polynucleotide and base editing activity of the amino acid sequence as shown in SEQ ID NO: 190 or SEQ ID NO: 3, wherein the stringent conditions are medium stringency conditions, medium-high stringency conditions, high stringency conditions or very high stringency conditions.

14. The base editor fusion protein according to claim 13, wherein The base editor fusion protein comprises any one of the sequences shown in SEQ ID NO:191-198.

15. A base editor fusion protein, wherein: It comprises the adenosine deaminase according to any one of claims 1 to 6, and the nucleic acid programmable nucleotide binding domain according to any one of claims 7 to 9, and the fusion protein structure is NH2-[N-terminal fragment of the nucleic acid programmable nucleotide binding domain]-[deaminase]-[C-terminal fragment of the nucleic acid programmable nucleotide binding domain]-COOH.

16. The base editor fusion protein according to claim 15, wherein the nucleic acid programmable nucleotide binding domain selects the nCas9 domain, and the insertion position of the adenosine deaminase is between amino acid positions 583-584, 768-769, 770-771, 776-777, 793-794, 905-906, 919-920, 1048-1063, 1049-1062, 1249-1250, 1263-1264 or 1276-1277 of SEQ ID NO:

61.

17. A polynucleotide encoding the adenosine deaminase according to any one of claims 1 to 6 or encoding the base editor fusion protein according to any one of claims 7 to 16, including but not limited to the nucleotide sequences shown in SEQ ID NOs. 2, 4, 156-165. A vector comprising the polynucleotide according to claim 17 .

19. A cell comprising the adenosine deaminase according to any one of claims 1 to 6, the base editor fusion protein according to any one of claims 7 to 16, the polynucleotide according to claim 17, or the vector according to claim 18.

20. A base editor system comprising the adenosine deaminase according to any one of claims 1 to 6, a nucleic acid programmable nucleotide binding domain, and a guide polynucleotide; Alternatively, it comprises a base editor fusion protein as claimed in any one of claims 7 to 16, and a guide multi-core Glycoside acid.

21. A pharmaceutical composition comprising the adenosine deaminase according to any one of claims 1 to 6, the base editor fusion protein according to any one of claims 7 to 16, the polynucleotide according to claim 17, the vector according to claim 18, the cell according to claim 19 or the base editor system according to claim 20, and a pharmaceutically acceptable carrier.

22. A kit comprising the adenosine deaminase according to any one of claims 1 to 6, the base editor fusion protein according to any one of claims 7 to 16, the polynucleotide according to claim 17, the vector according to claim 18, the cell according to claim 19, or the base editor system according to claim 20.

23. A delivery system comprising the adenosine deaminase of any one of claims 1 to 6, the base editor fusion protein of any one of claims 7 to 16, the polynucleotide of claim 17, the vector of claim 18, the cell of claim 19 or the base editor system of claim 20, and a delivery medium.

24. A method for base editing of a nucleic acid, comprising the step of contacting a nucleic acid whose base is to be edited with the base editor system according to claim 20.

25. Use of the adenosine deaminase according to any one of claims 1 to 6, the base editor fusion protein according to any one of claims 7 to 16, the polynucleotide according to claim 17, the vector according to claim 18, the cell according to claim 19, the base editor system according to claim 20, the pharmaceutical composition according to claim 21, or the delivery system according to claim 23 in treating diseases associated with or caused by point mutations or in preparing drugs for treating diseases associated with or caused by point mutations.

26. The use according to claim 25, mainly comprising use in treating diseases related to the PCSK9 target, and / or use in preparing drugs for treating hypercholesterolemia, transthyretin amyloidosis, and β-hemoglobinopathy.

Citation Information

Cited By

  • Deaminase for base editing and variants thereof

    CN119162157A

  • Adenosine deaminase, fusion protein, base editor system, and use thereof

    WO2026214774A1